Magnetic Resonance Imaging of Breast Cancer Brain Metastasis Progression and Responses to Radiotherapy by Murrell, Donna H.
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
8-12-2016 12:00 AM 
Magnetic Resonance Imaging of Breast Cancer Brain Metastasis 
Progression and Responses to Radiotherapy 
Donna H. Murrell 
The University of Western Ontario 
Supervisor 
Dr. Paula Foster 
The University of Western Ontario 
Graduate Program in Medical Biophysics 
A thesis submitted in partial fulfillment of the requirements for the degree in Doctor of 
Philosophy 
© Donna H. Murrell 2016 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Medical Biophysics Commons 
Recommended Citation 
Murrell, Donna H., "Magnetic Resonance Imaging of Breast Cancer Brain Metastasis Progression and 
Responses to Radiotherapy" (2016). Electronic Thesis and Dissertation Repository. 3961. 
https://ir.lib.uwo.ca/etd/3961 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
  
 
 
i 
Abstract 
Introduction: The incidence of brain metastasis due to breast cancer is increasing and 
prognosis is poor. Treatment is challenging for this disease because systemic therapy has 
limited efficacy due to the presence of the blood-brain barrier. In addition, it is thought 
that disseminated dormant cancer cells persist in metastatic organs and may evade 
treatment, thereby facilitating a mechanism for later recurrence. Methods: In this thesis, 
we use contrast-enhanced MRI and high resolution anatomical MRI to characterize 
blood-brain barrier integrity associated with the development of metastases in the mouse 
brain due to HER2+ breast cancer in the SUM-190-BR3, JIMT-1-BR3, and MDA-MB-
231-BR-HER2 experimental models. We further use these imaging techniques along with 
novel micro-irradiation technology to investigate the impact of whole brain radiotherapy 
on the growth and blood-brain barrier permeability of brain metastases in the MDA-MB-
231-BR-HER2 model. Finally, we employed MRI cell tracking in this model to study the 
fate of proliferative and non-proliferative cancer cells after early radiotherapy. Histology 
and immunohistochemistry was performed on brain sections corresponding to MRI to 
validate and further investigate radiological findings. Results: Herein, we show 
substantial heterogeneity in tumor permeability across three models of brain metastasis 
due to HER2+ breast cancer. We also demonstrate that whole brain radiotherapy 
following diagnosis of brain metastasis in mice can mitigate, but not eliminate, tumor 
growth in the MDA-MB-231-BR-HER2 model. Furthermore, radiotherapy did not impact 
blood-brain barrier permeability associated with metastases. In comparison, early WBRT 
was used successfully in mice as a preventative treatment against brain metastatic 
growth. Still, cellular MRI revealed the persistence of non-proliferative cancer cells in the 
brain regardless of treatment time point or efficacy against metastasis. Conclusions: 
Consideration of tumor permeability in brain metastasis models is important when 
investigating novel therapeutics as blood-brain barrier integrity varies substantially across 
models of the same disease. Radiotherapy did not increase tumor permeability; however, 
other strategies should be investigated. Whole brain radiotherapy is effective as a 
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preventative treatment against brain metastasis, but is not curative when delivered after 
MRI-detectable tumors have developed. The persistence of iron-retaining non-
proliferative cancer cells after prophylactic radiotherapy suggests these dormant cells 
may be able to evade treatment and later could contribute to cancer recurrence. 
 
Keywords 
MRI, breast cancer, brain metastasis, tumor permeability, dormancy, radiotherapy, cell 
tracking, micron-size particles of iron oxide (MPIO), bSSFP, gadolinium 
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Chapter 1  
1 Introduction 
This thesis employs magnetic resonance imaging (MRI) for detection of brain metastasis 
due to breast cancer in animal models and investigates metastatic response to 
radiotherapy. This introductory chapter discusses the concepts of brain metastasis, cancer 
dormancy, neuroimaging in neuro-oncology, cellular MRI, and treatment options for 
brain metastasis in order to provide background and motivation for the research presented 
in this thesis. 
1.1 Motivation and Overview 
True metastatic burden in the brain may be substantially underestimated by clinical 
imaging protocols (Figure 1.1A). Contrast-enhanced MRI is the gold standard for cancer 
imaging in the brain; however, there may be tumors that do not take up the contrast agent 
and therefore would go undetected. Furthermore, there may be a population of dormant, 
solitary cancer cells present in the brain (Figure 1.1B). These two categories of cancer 
metastasis represent distinct therapeutic targets and may be spared by therapies that target 
permeable metastases and actively dividing cancer cells, leading to later disease 
recurrences. This poses a challenge for effective cancer detection and therapy. 
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Figure 1.1: Schematic of brain metastases due to breast cancer in a mouse model.   
In A the green-colored brain tumors represent those brain metastases that are 
detected by gadolinium-enhanced MRI; these metastases take up contrast agent.  In 
B these metastases are again shown in green along with (i) orange-colored brain 
tumors that are detectable by MRI using another sequence that exploits endogenous 
tumor contrast; these metastases do not take up contrast agent, and therefore are 
not detected by gadolinium-enhanced MRI, and (ii) black regions of signal void that 
represent non-proliferative or dormant cancer cells which may be present in the 
brain but which also would go undetected by conventional MRI techniques. 
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In this thesis, experimental imaging techniques are presented to identify tumors in mouse 
brains that do not take up MRI contrast and to monitor the fate of individual cancer cells 
in animal models of metastatic breast cancer. Chapter 2 investigates contrast agent uptake 
by tumors in three experimental models and demonstrates substantial heterogeneity 
between tumors and between models. In chapter 3, mice are treated with radiotherapy to 
investigate treatment response between tumors that uptake the contrast agent and those 
that do not; further, this work seeks to understand if it is possible to increase tumor 
permeability with irradiation, thereby allowing increased contrast agent uptake within the 
tumor. In chapter 4, radiotherapy is delivered early in metastatic progression and cell 
tracking techniques are employed to monitor the fate of cancer cells over time and to 
understand how different cancer cell subpopulations respond to treatment. Finally, 
chapter 5 summarizes the conclusions and significance of this thesis, discusses 
experimental limitations, and presents ideas for future work to build on the results 
presented in this thesis.  
1.2 Metastatic Breast Cancer 
Breast cancer is the most common cancer in Canadian women and is expected to affect 1 
in 9 women in her lifetime [1]. Most deaths due to this disease are a result of breast 
tumors spreading to regional and distant sites – commonly liver, lung, bone, and brain – 
by a process called metastasis [2,3,4]. Early detection of metastasis is challenging and 
current therapies ultimately fail in the metastatic setting.  
Breast cancer is a complex and heterogeneous disease that can be classified several ways, 
including by histopathology, molecular subtype, and grade. Brain metastases can occur in 
patients with all types of breast cancer; however, this thesis focuses on breast cancer that 
overexpresses the human epidermal growth factor receptor 2 (HER2+ subtype) as these 
patients are at high risk for developing brain metastasis [4, 5].  Historically, brain 
metastases were a late complication in metastatic disease; however, advances in systemic 
anti-HER2 therapies have significantly improved extra-cranial disease control and the 
brain is increasingly becoming a first site of relapse in HER2+ breast cancer patients.  
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1.2.1 Brain Metastasis 
Three large studies using population-based cohorts have estimated the incidence of brain 
metastasis due to breast cancer to range from 5.0 – 32.6% [6, 7, 8]. Still, this is likely an 
underestimation of true brain metastasis incidence; some metastases may be overlooked 
because patients are asymptomatic, or already too sick and a diagnosis would be 
irrelevant to their care. Historically, autopsy studies have reported substantially higher 
proportions of patients with brain metastasis than what was diagnosed clinically [5]. 
The incidence of brain metastasis is increasing in the clinic. This is partially because the 
ability to detect small tumors has improved as better neuroimaging techniques have 
become available. Furthermore, brain metastases often manifest later in cancer 
progression; recent advances in treatment options for breast cancer has resulted in longer 
patient survival and better control of extra-cranial disease thereby allowing the brain and 
central nervous system (CNS) to become a sanctuary site for metastases. Thus the 
prevalence of brain metastasis is expected to rise further as systemic therapy improves.  
For example, HER2+ breast cancer patients treated with trastuzumab develop CNS 
metastases in 31-48% of cases and 33-50% of those women are responding to therapy or 
have stable disease at other sites when diagnosed with CNS involvement [10-13].  
1.2.2 Metastatic Colonization 
Cancer metastasis is an inefficient process [2]. Blood samples from cancer patients may 
show high numbers of circulating cancer cells; however, few actual metastatic tumors 
result [14]. This suggests that cancer cell survival during the metastatic cascade must be 
low, or conditions for cell proliferation in the microenvironment are highly specific. To 
achieve the first steps of the metastatic cascade, a cell must escape the primary tumor, 
invade local tissue, and intravasate into the vasculature [15]. It must then survive in the 
blood and disseminate via the circulation. Many cancer cells will reach the brain in this 
way and some will arrest in the microcirculation. Initially, cells arrest at blood vessel 
branches where the cell to vessel diameter ratio approaches one and eventually single 
cancer cells may then extravasate into the surrounding tissue [16]. Cancer cells can 
execute these steps with relatively high efficiency [15]. Once the metastatic cancer cell 
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arrives in the brain, it may experience one of three fates (Figure 1.2): (1) it may die; (2) it 
may remain viable but dormant; or (3) it may proliferate and form a brain metastasis. 
Many cells do not survive the required steps for brain colonization [15, 17]. This relies on 
cancer cell survival outside of the vasculature and invasion of the surrounding tissue, 
both of which are inefficient steps in the metastatic cascade [15]. Subsequent 
development or recruitment of tumor-associated vasculature is required for 
macrometastatic growth; until this vasculature develops, surviving extravasated cancer 
cells adhere to the outer vessel wall to migrate and access oxygen and nutrients [16, 18]. 
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Figure 1.2: Brain colonization by metastatic cancer cells requires that cells survive 
in the vasculature and arrest in the microcirculation. Single cancer cells may then 
extravasate out of the vasculature and into the brain where they will experience one 
of three fates: (1) death, (2) dormancy, where the cell remains viable but non-
proliferative, or (3) proliferation to form brain metastases. 
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1.2.3 The Unique Brain Microenvironment 
The brain microenvironment offers a unique metastatic site with vasculature that differs 
from most other organs. Extra-cranial capillaries are thin and composed of a single 
endothelial cell layer with various combinations of fenestra, clefts, and pores [19]. 
Structurally, this allows for uncomplicated exchange of oxygen, carbon dioxide, 
nutrients, and waste between the blood and surrounding tissue. In contrast, a highly 
selective barrier surrounds capillaries in the brain. It is comprised of endothelial cells 
connected by tight junctions, a basement membrane, pericytes, and astrocytes [19]. 
Together, these components form the blood-brain barrier (BBB), which serves to protect 
the brain by tightly regulating the diffusion of substrates from the blood into the brain 
parenchyma. The BBB has very low passive permeability and high levels of efflux 
transporters, which maintain the internal brain microenvironment and prevent 
neurotoxicity [19-21]. Under normal conditions, the BBB is extremely exclusive and 
prevents most traditional systemically administered chemo- and molecular therapeutics 
from entering the brain in sufficient concentrations for cytotoxicity.  
As a cancer cell extravasates from a brain capillary, it penetrates the BBB and the 
protective cells surrounding the vasculature are displaced. This compromises BBB 
integrity and a new barrier, known as the blood-tumor barrier (BTB), is formed in its 
place around the growing tumor. Relatively little is known about the BTB in patients, but 
its patency appears to vary substantially. For example, tumor detection by clinical 
imaging relies on extravasation of contrast agents across the BBB/BTB; yet, breast 
cancer therapeutics such as paclitaxel, doxorubicin, and trastuzumab, which have been 
highly successful for treating extra cranial metastases, do not cross the BBB/BTB well 
and are ineffective against brain metastases [10, 22, 23]. Notably, newer therapeutics, 
such as capecitabine and lapatinib, appear to penetrate the BTB; however, drug uptake 
within individual brain metastases and among patients is highly variable [24]. It is 
presumed that partial exclusion from the brain causes these and other chemotherapies to 
fail, thus rendering the brain a ‘sanctuary site’ for metastatic growth. 
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The development of a brain metastasis creates an increasingly high demand for oxygen 
and nutrients. For most tumors, this need is typically met by the promotion of tumor-
associated neovasculature in a process called angiogenesis. The brain is a unique 
metastatic site because it is the most highly vascularized organ in the human body and, 
for this reason, cerebral metastases may grow without inducing angiogenesis. Instead, 
tumors can exploit the rich pre-existing vasculature of the brain through alternative 
vascularization mechanisms. Tumors may co-opt the innate dense capillary bed in the 
brain by growing alongside pre-existing microvessels and invading the surrounding brain 
tissue [25-27]. Co-opted vessel density is lower within brain metastases compared to 
normal brain; however, dilated vessels within tumors compensate to meet increased 
metabolic demands [27]. The role of angiogenesis in brain metastasis development was 
studied by Leenders and colleagues; they investigated the outcome of anti-angiogenic 
drugs on the development of brain metastasis and found that although angiogenesis was 
blocked, tumors continued to progress via co-option of the pre-existing vasculature [25]. 
Thus, brain tumors may develop without angiogenesis.  
1.2.4 Dormancy 
If cancer cells survive in the metastatic organ, they may co-exist in three forms. Solitary 
cells may remain in a state of quiescence whereby they remain viable but non-
proliferative for an extended period of time; this process of dormancy is likely 
responsible for clinical recurrence. If solitary cells begin to proliferate, they may form 
‘dormant’ micrometastases – proliferative tumors where net tumor size is unchanged due 
to balanced proliferation and apoptosis – or, they may become actively growing and 
recruit vasculature by either angiogenic or vessel co-option strategies. These three states 
of existence represent vastly different cancer biology with significant implications for 
detection, therapy, and patient outcomes. The factors that control the balance between 
dormancy and proliferation are poorly understood, but are subject of much ongoing 
research and discussion [28-34].  
Notably, no unique markers have been discovered to identify dormant cancer cells.  As a 
consequence, studying their nature in animal models is limited to assessing lack of 
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proliferation and apoptosis by histology ex vivo or by tracking non-proliferative cells via 
retention of imaging markers in vivo. An important study by Naumov and colleagues 
investigated dormancy using intravital video microscopy to image fluorescent 
nanosphere-labeled mammary carcinoma cells (D2.0R and D2A1 cell lines) over time in 
the mouse liver [35]. They reported large proportions of solitary cells observed in vivo 
and in histology. These apparently dormant cancer cells were then recovered from the 
liver tissue and re-grown in vitro where they regained their proliferative phenotype. 
Importantly, these cells also uniformly grew primary tumors when re-injected into the 
mammary fat pad of mice, suggesting dormant cancer cells are viable and their growth 
arrest is reversible. Recent studies have employed MRI-based cell tracking to monitor 
dormant cancer cells in vivo over time and this is further discussed in the subsection 
“Cellular MRI” [17, 36-38].  
Dormancy, both at the single cell level as well as at the micrometastasis stage, is believed 
to provide a reservoir of cells that lie in wait until some elusive trigger causes them to 
proliferate and progress into clinically relevant tumors. This phenomenon presents a 
significant treatment challenge because its biology deviates from traditional 
understanding of malignant cancer growth. Current chemotherapies target highly 
proliferating cells and therefore dormant cells persist, unaffected [38, 39]. 
1.2.5 Experimental Models for Breast Cancer Brain Metastasis 
Laboratory mouse models are most commonly used to study brain metastasis in vivo. Few 
experimental model systems specific for brain metastases due to breast cancer exist [40-
43]. These models provide insight into brain metastatic development and enable 
investigation that is not possible in the clinic. 
Both syngeneic and xenograft transplant models exist. Syngenic transplant models 
introduce murine cancer cells into mouse recipients of the same genetic background.  An 
example of this type of model is the murine 4T1-BR5 brain metastatic breast cancer cell 
line injected into BALB/c mice [43, 44]. This type of model offers the opportunity to 
investigate tumor development in the presence of a fully functioning immune system; 
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however it lacks specificity to human cancer and may not reflect human disease 
heterogeneity. Xenograft transplant models inoculate immune-compromised hosts with 
human cancer cell lines that are derived from patient tissue samples, such as in the MDA-
MB-231-BR model [40, 41]. Several mouse strains are available for this research with 
varying degrees of immune-deficiency.  This approach lacks functioning immune 
response, but allows for the direct metastasis modeling that is relevant to human cancer 
development. 
Syngenic and xenograft transplant models can be initiated in similar ways; cancer cells or 
tumor fragments can be delivered ectopically or hematogenously for brain metastasis 
development. Some experimental models involve brain metastases that can form 
spontaneously from a primary tumor. This can be advantageous because the metastatic 
cascade develops naturally; however, spontaneous models are not frequently reported in 
breast cancer research. In etctopic injection models, breast tumor cells or tumor 
fragments are implanted directly into the brain parenchyma or cerebrospinal fluid space 
for metastasis development. This model is the simplest to initiate and can be useful 
because it develops only a single tumor in a known location. Moreover, it does not 
require the use of specific metastatic or brain-tropic cell lines. Though simple, 
implantation models are limiting because they bypass natural brain colonization and 
therefore may not adequately model all aspects of metastatic growth. Hematogenous 
delivery of cancer cells mimics parts of natural metastatic spread by transport of cancer 
cells via the circulation and therefore creates a more physiologically relevant model. A 
cancer cell suspension can be injected into the beating left ventricle of the mouse heart 
(intra-cardiac injection) or into the internal carotid artery (intra-arterial injection) for 
delivery to the brain. Intra-cardiac injection results in 3.5 – 9.5% of cells delivered to the 
mouse brain by cardiac output [45, 46]. This model is relatively straightforward, but 
technically challenging and cancer cells also disseminate to other sites and may cause 
unwanted tumor growth. Intra-arterial injection improves direct cell delivery to the brain 
and decreases the potential for extra-cranial metastatic growth [47, 48]. This model is 
difficult to initiate and advanced microsurgical skill is required to successfully execute 
inoculation procedures. 
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Cell lines that preferentially grow in the brain have been developed to use in breast 
cancer brain metastasis models, such as MDA-MB-231-BR, MDA-MB-231-BR-HER2, 
JIMT-1-BR3, SUM-190-BR3, and 4T1-BR5 (Table 1.1) [40-43, 49]. These brain 
metastatic cell lines are derived from primary breast cancer cell lines by repeated rounds 
of selection. A parental primary cancer cell line that is known to be metastatic is grown in 
culture and introduced hematogenously into mice. Metastases will develop into various 
organs over time, including in the brain. Brain tumors are isolated and harvested; these 
cells are then re-grown in culture [40]. This is referred to as a ‘brain derivative’ of the 
parental cell line. Biased tropism for the brain is improved by several sequential rounds 
of re-injection of the ‘brain derivative’ cell line, isolation of brain tumors, and re-growth 
in culture. These cells lines then inherently prefer the brain microenvironment, which is 
advantageous in hematogenous delivery models to mitigate metastatic growth in other 
organs.  
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Table 1.1: Brain-tropic (‘BR’) breast cancer cell lines derived from parental cell 
lines by successive selection rounds for use in preclinical model systems 
Cell Line Origin 
MDA-MB-231-BR Human breast carcinoma; ER-/PR-/HER2- 
MDA-MB-231-BR-HER2 Above, transfected with HER2 
JIMT-1-BR3 
Human breast carcinoma previously isolated from a 
Herceptin-resistant patient; ER-/PR-/HER2+ 
SUM-190-BR3 Human inflammatory breast cancer; ER-/PR-/HER2+ 
4T1-BR5 Murine breast cancer 
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Complete research models that accurately reflect clinical disease are rare. The MDA-MB-
231-BR cell line delivered by intra-cardiac injection has been well characterized and 
produces a model that is similar to resected human brain metastases from breast cancer in 
many ways, including proliferation and apoptosis rates [50]. For this reason, the ‘231BR’ 
model has been used extensively to study brain metastases from triple-negative breast 
cancer [17, 40, 50-56]. Moreover, the 231BR cell line was transduced with HER2 cDNA 
(MDA-MB-231-BR-HER2) to create a brain metastasis model for the HER2 subtype of 
breast cancer [41]. This resulted in the formation of greater numbers of large metastases 
(>50 µm) compared with the non-HER2 version, but was irrelevant to the development of 
micrometastases [41, 51]. This thesis employs intracardiac injections of the SUM-190-
BR3, JIMT-1-BR3, and MDA-MB-231-BR-HER2 cell lines to initiate experimental 
models of brain metastasis due to HER2+ breast cancer in nude mice.  
1.3 Magnetic Resonance Imaging in Oncology 
MRI is a non-invasive and non-ionizing imaging modality that can provide excellent soft 
tissue contrast with a wide range of contrast mechanisms; it is therefore an ideal method 
to diagnose cancer and longitudinally monitor progression and treatment responses. MRI 
relies on the properties of hydrogen atoms (protons) to generate an image. In MRI, 
protons within a subject are exposed to a strong main magnetic field (B0) that causes 
them to align and precess about B0. A radiofrequency (RF) excitation pulse is then 
applied temporarily to change the orientation of the net magnetization vector away from 
alignment with B0. Once the RF is turned off, the protons both dephase and also relax 
back into alignment with B0, emitting energy that produces a signal that can be detected 
and translated into an image by advanced computer processing.  Protons in different 
tissues and biological states will dephase and realign at different rates. Image contrast in 
MRI can be generated in many different ways by exploiting these differences. A brief 
overview of image contrast formation, pulse sequences, and contrast agents is given in 
the following sections; further discussion of basic MRI physics and image formation can 
be found in several textbooks, including an excellent overview by McRobbie et al., “MRI 
from Picture to Proton” [57].   
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1.3.1 Generating Image Contrast 
In general, MR images have contrast that is ‘weighted’ by proton density (PD), spin-
lattice relaxation time (T1), or spin-spin relaxation time (T2). PD-weighted images create 
regions of brightness where there are higher numbers of hydrogen atoms within a given 
volume. T1-weighted images illustrate contrast that reflects how quickly protons realign 
with the main magnetic field after RF excitation. Fat-based tissues have a short T1 and 
appear bright in a T1-weighted image, whereas fluids, such as blood, have long T1 values 
and appear dark. T2-weighted images depict rates of dephasing after RF excitation. 
Contrary to T1-weighted images, in T2-weighted images, fat appears dark due to short T2 
values and fluid appears bright due to long T2.  Sample tissue relaxation times at 
clinically relevant magnetic field strengths are shown in Table 1.2 [57, 58]. For most 
tissues T1 relaxation times increase significantly as field strength increases and T2 
relaxation times stay close to the same. 
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Table 1.2: T1 and T2 relaxation times for various tissue types at 1.5 T and 3 T 
magnetic field strengths.   
Tissue type 
Animal 1.5 T 3 T 
  T1 (ms) T2 (ms) T1 (ms) T2 (ms) 
Liver mouse 576 46 812 42 
Skeletal muscle mouse 1008 44 1412 50 
Heart mouse 1030 40 1471 47 
Kidney rat 690 55 1194 56 
White matter cow 884 72 1084 69 
Gray matter cow 1124 95 1820 99 
Spinal cord rat 745 74 993 78 
Blood human 1441 290 1932 275 
Fat human 200 - 382 68 
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The contrast of an MR image is controlled by the pulse sequence, which contains 
programmed manipulations of the timing and duration of RF and gradient pulses. The 
combination of pulse timing and duration can exploit the different PD, T1, or T2 in 
tissues of interest. There are two fundamental types of pulse sequences for MR imaging: 
spin echo (SE) and gradient echo (GE). Both SE and GE sequences can create images 
with PD, T1, or T2 weighting. SE sequences produce excellent quality images, but take a 
relatively long time to acquire. GE sequences are much faster; however, they are affected 
by main magnetic field inhomogeneity, which causes T2 values to be shorter. Pure T2 
contrast is not possible in GE sequences and the contrast is created by the combination of 
T2 plus magnetic field inhomogeneity, which together is known as T2* [57].  
In cancer research, MRI contrast can be manipulated to highlight malignant tissue in 
anatomical images and derive additional information about tumor biology, function, or 
treatment response using several different image acquisition techniques. Conventional 
MRI in oncology includes analysis of T2-weighted images as well as pre- and post-
contrast T1-weighted images. In addition to these, many additional novel contrasts are 
being investigated and translated to application in the clinic. Tumor perfusion and 
vascularity can be studied using dynamic susceptibility contrast-enhanced MRI (DSC-
MRI) or dynamic contrast-enhanced MRI (DCE-MRI) [59-61]. Cellularity of cancers can 
also be studied by a technique called diffusion-weighted imaging (DWI) [61-63]. 
Magnetic resonance spectroscopy (MRS) can be employed to investigate cancer 
biochemistry, and hyperpolarized MRI can be used to study tumor metabolism [59, 63-
65]. Chemical exchange saturation transfer MRI (CEST MRI) can measure tumor pH and 
multinuclear MRI can image other nuclei that are abundant in cancer growth [66, 67]. 
Finally, cell tracking can be used in preclinical models to monitor cancer cell fate and 
molecular imaging can provide a targeted method to detect changes in cancerous tissue 
prior to anatomical changes occurring [17, 36, 37, 68, 69].  
This thesis employs two pulse sequences to investigate brain metastasis development. 
Contrast-enhanced T1-weighted SE images are acquired to study BBB integrity and 
tumor permeability. The balanced steady state free precession (bSSFP) pulse sequence is 
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used to image tumor development in the brain and track iron-labeled cancer cells. These 
sequences are discussed in the following section.  
1.3.2 Relevant Pulse Sequences 
The SE pulse sequence is a common and relatively straightforward image acquisition. 
The contrast is produced by two main parameters: repetition time (TR) and echo time 
(TE). The TR refers to the time between RF excitation pulses in consecutive repetitions 
of the pulse sequence. The TE is the time between the RF excitation pulse and the echo. 
Short TE and TR create T1-weighted images [57].  
In the magnet, but prior to initiating the pulse sequence, the magnetization vector is 
aligned with B0 and points along the z-axis. In the SE pulse sequence, a 90° RF pulse is 
applied and tips the magnetization vector into the x-y plane. The spins begin to dephase 
and realign with B0 in a process known as free induction decay (FID). After a short 
duration TE/2, a 180° RF pulse is applied to refocus the spins; this brings the spins back 
into phase at TE when the echo is formed and the signal is acquired [57]. During this 
series of excitations and readout, spatial localization of the signal is achieved by applying 
magnetic fields that vary with position, known as gradient fields, in the x- y- and z- 
directions. A slice-select gradient (Gz) is turned on during the 90° and 180°RF excitation 
pulses to determine the position of the imaging slice along the z-direction. A phase-
encoding gradient (Gy) is turned on briefly between the excitation pulses, which causes a 
temporary change in precession speed and causes protons to acquire phase shifts based on 
their position in the y-direction [57]. To acquire a complete image, this phase-encode 
gradient is applied with different strengths during each TR. Frequency-encoding 
gradients (Gx) are turned on during readout and cause protons to precess at different 
frequencies along the x-axis. The RF signal acquired during readout is digitized and used 
to fill a data matrix known as k-space, which can then produce an image after applying a 
Fourier transform.  
The bSSFP pulse sequence is a type of GE sequence that is known as Balanced Fast Field 
Echo (balanced FFE), True Fast Imaging with Steady-state Precession (True FISP), or 
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Fast Imaging Employing Steady-state acquisition (FIESTA) on Philips, Siemens, and 
General Electric MRI scanners respectively [57]. A typical GE sequence employs a RF 
pulse with flip angle α, which tips the magnetization vector towards the x-y plane when 
applied. Slice-select and phase-encoding gradients are used as in the SE pulse sequence. 
Dephasing of the transverse magnetization is accelerated by the application of a 
dephasing readout gradient and reversed by a rephasing gradient with opposite polarity to 
acquire signal with short TE. Dephasing due to magnetic field inhomogeneity is not 
rephased in this process and GE sequences are therefore affected by T2* [57].  
In the bSSFP pulse sequence, signal is conserved due to lack of gradient-induced 
dephasing during each TR. This is achieved by the application of compensating gradient 
pulses with equal strength but opposite polarity, such that the dephasing induced by a 
negative gradient is “balanced” by that of a positive gradient. The result is a highly SNR 
efficient pulse sequence with interesting T2/T1-weighted image contrast [70, 71]. 
Scheffler and Lehnhardt give an excellent illustration and description of how the 
magnetization vector is manipulated during bSSFP and further discuss the principles of 
this pulse sequence [70].   
1.3.3 Contrast Agents 
Contrast media is often employed in MRI for cancer research to increase the signal 
difference between normal tissue and primary tumors, metastatic lesions, or cancer cells. 
The most common MRI contrast agents are Gadolinium-based chelates (Gd), which are 
strongly paramagnetic and increase the T1 relaxation rate (1/T1) of nearby nuclei causing 
brightness where Gd accumulates. Images are typically acquired before and after 
intravenous (iv) injection of these agents. In most of the body, Gd initially travels through 
blood vessels and then extravasates into the interstitial space or undergoes renal 
clearance. Post-Gd T1-weighted images can be used to visualize vasculature in the early 
stages, or tissue enhancement patterns at later stages. Zhou and Lu recently reviewed Gd-
based contrast agents for MR cancer imaging [72].   
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Iron oxide nanoparticles are another class of MRI contrast agents that create negative 
contrast by causing local magnetic field inhomogeneities [73]. This causes increased 
dephasing and increases the T2 relaxation rate (1/T2 or 1/T2*) of nearby nuclei, resulting 
in areas of signal void. These agents come in a range of sizes, including: micron-sized 
particles of iron oxide (MPIO), superparamagnetic iron oxide nanoparticles (SPIO), and 
ultra-small SPIO (USPIO) [74]. The smallest are USPIO and are referred to as blood pool 
agents; imaging performed before and after the iv administration of USPIO allows for 
characterization of tumor vasculature and assessment of vascular volume [75-77]. 
Imaging cancer cells using iron oxide nanoparticles is further discussed in “Cellular 
MRI.” 
1.3.4 Neuroimaging in Neuro-Oncology 
Suspicion of brain metastasis is evaluated by imaging – usually computed tomography 
(CT) or MRI – where lesions of several millimeters in size are generally radiographically 
detectable. Contrast-enhanced cranial CT can detect many brain metastases; however, 
diagnosis by MRI is considered superior due to better soft tissue contrast, ability to detect 
smaller tumors, fewer artifacts, and ability to acquire images in all three planes and 
without the risk of ionizing radiation dose to the patient [78]. The radiological appearance 
of brain metastasis is diverse and varies substantially with primary tumor origin. 
Generally, the lesion is well demarcated from the brain parenchyma, though it may also 
be surrounded by cerebral edema.  
Contrast-enhanced T1-weighted (T1w) MRI is widely regarded as the most accurate 
method for clinical brain tumor detection [79, 80]. In healthy brain, the BBB prevents Gd 
from diffusing out of the circulation. By contrast, the BBB is often disrupted in the local 
area of a tumor due to tumor infiltration, increased vascular permeability, or poorly 
constructed angiogenic vessels. Tumors are identified by diffusion of Gd across the 
impaired BBB/BTB, which results in signal enhancement (brightness) in the post-Gd 
image.  
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A clinical MRI session includes many image acquisitions to create different contrasts and 
gain information about the structure of the brain and tumor. Figure 1.3 illustrates some 
example images from a brain metastasis imaging protocol in a pre-radiotherapy MR 
simulation session at the London Regional Cancer Program.   
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Figure 1.3: A breast cancer patient with brain metastasis. Axial T2-weighted fast 
spin echo (T2 FSE) imaging illustrates substantial edema surrounding the tumor. 
The sagittal fluid-attenuated inversion recovery (FLAIR) image has similar contrast 
to the T2 FSE, but cerebrospinal fluid signal is suppressed for better imaging of 
lesions near the ventricles. T1-weighted pre- and post-Gd coronal FSE and axial fast 
spoiled gradient echo (FSPGR) images demonstrate heterogeneous signal 
enhancement within the tumor mass. 
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Employing multiple contrast mechanisms aids radiologists to differentiate a brain 
metastasis from a primary brain tumor, cerebral abscess, or stroke. Furthermore, these 
protocols may be used to evaluate response after treatment. MR sequences that are used 
for brain metastasis visualization and evaluation, as well as tumor appearance, are 
described in Table 1.3 [80-82].  
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Table 1.3: General MRI protocols for brain metastasis detection and evaluation. 
MRI Protocol Tumor Appearance 
T1-weighted 
pre Gd iv 
 
 
 
post Gd iv 
 
 
isointense or mildly hypointense; melanin may cause 
hyperintensities in some brain metastases due to melanoma; 
hemorrhagic  metastases may also be hyperintense 
 
intense enhancement throughout, in nodes, or ring-enhancing 
 
T2-weighted hyperintense; melanin may cause some brain metastases due to 
melanoma to appear hypointense 
 
Diffusion-weighted 
imaging 
 
hyperintense on apparent diffusion coefficient map 
MR perfusion increased cerebral blood volume and blood flow 
 
MR spectroscopy increased metabolic activity; choline and N-acetyl aspartate are 
common metabolites that are compared with creatine, which is 
used as an internal control 
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If imaging suggests clinical presentation of metastatic lesions in the brain, stereotactic or 
open biopsy may be indicated to confirm diagnosis and characterize the metastasis [79]. 
Though invasive, biopsy is useful to rule out inflammation or infection, which may 
appear similar to a metastatic lesion by radiology or MRI.  
1.3.5 Pre-clinical Imaging of Blood-Brain Barrier Integrity  
Several groups have used Gd-enhanced MRI to evaluate the permeability of the 
BBB/BTB associated with brain tumors in experimental rodent models [25, 49, 61, 83, 
84]. Figure 1.4 shows T1-weighted images of the mouse brain pre- and post-Gd.  After 
Gd, 231-BR-HER2 brain metastases are detectable as regions of signal enhancement due 
to local disruption in the BBB, which allows Gd to cross and accumulate. Using this 
technique, Percy and colleagues reported substantial heterogeneity in the permeability of 
breast cancer brain metastases, even within the same brain [84].  Many of the metastases 
became permeable with time, suggesting that as they develop changes to the tumor 
vasculature compromise the integrity of the BBB. At the last imaging time point there 
were approximately 4 times as many Gd-permeable metastases as Gd-impermeable. Gd-
permeable metastases were significantly larger than non-permeable tumors, however, size 
alone was not sufficient to predict permeability [84]. The impermeability of the BBB 
hinders the delivery of chemotherapeutic agents to the brain, limiting the success of 
pharmacological approaches to treat brain metastases [22-24].  The ability to use MRI to 
noninvasively assess the permeability status of brain metastases will be important for 
understanding the process of brain metastasis and for evaluating the development of 
BBB-permeable chemotherapeutic drugs.   
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Figure 1.4: T1-weighted SE images of approximately the same slice in a mouse brain 
acquired pre (left) and post (right) Gd contrast agent administration.  Brain tumors 
are not detectable before Gd (left). After Gd, 231-BR-HER2 metastases are 
detectable as regions of signal enhancement due to local disruption in the BBB, 
which allows Gd to cross and accumulate (right). 
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1.3.6 Cellular MRI 
Iron oxide nanoparticles are the most commonly used contrast agents for MRI cell 
tracking and the development of this technology has been thoroughly reviewed [85-90]. 
These agents create negative contrast in T2- or T2*-weighted proton MR images because 
the iron within them causes a local magnetic field inhomogeneity that leads to shorter 
transverse (T2) and effective transverse (T2*) relaxation times of nearby nuclei; this 
results in MR signal loss, which extends to occupy more space in an image than the 
dimensions of the contrast agent or cell itself, and is known as the “blooming artifact” 
[73]. The degree of contrast in an MR image is derived from the ability of iron oxide 
nanoparticles to change local relaxation rates (R2*=1/T2*), which depends on relaxivity 
values and contrast agent concentration; it is also sensitive to imaging parameters such as 
field strength, pulse sequence, resolution, and SNR [73, 89, 91-93]. Iron-labeled cells 
may appear as large areas of hypointensity or discrete regions of signal void in MR 
images depending on cell density in the target organ.  
Many different iron oxide nanoparticles exist as MRI contrast agents and they fall into 
three categories based on size. Kochinkski and colleagues recently reviewed iron oxide 
contrast agents for MRI and compared the properties and clinical approval status of 
several commonly used agents in the field [89]. In general, MPIO are the largest with 
diameters ≥ 1 µm and have the highest iron loading per particle. SPIO are relatively 
smaller at about 50-100 nm, and the smallest agents are USPIO at ≤50 nm in diameter 
[74, 89]. Selection of an MPIO, SPIO, or USPIO contrast agent for imaging depends on 
the application. The iron content of a single MPIO particle is about 1 pg Fe/particle and is 
equivalent to 1.5 million SPIO particles or 4.3 million USPIO [94]. Labeling cells with 
MPIO therefore offers the ability to substantially increase iron content within cells with a 
reasonable contrast agent volume and improves cell detectability in vivo, even at low 
numbers. Notably, single cell detection is possible, even at clinical field strengths, with 
MPIO or SPIO cell labeling [17, 73, 95-97]. Applications with MPIO are limited to 
preclinical investigation because the polymer matrix composition of these particles is not 
biodegradable.  
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Cell imaging using MRI has shown great utility in preclinical studies; however 
widespread use of MRI cell tracking in the clinic has not yet been achieved. This is 
largely due to the limited availability of commercial, FDA approved imaging agents. 
Ferumoxides (trade names: Feridex or Endorem) and ferucarbotrans (trade name: 
Resovist) are FDA-approved SPIO contrast agents used clinically for liver imaging; 
however these products were withdrawn from the market [98]. Now, in the absence of 
approved iron-oxide imaging agents, FDA-approved iron replacement therapies, such as 
Ferumoxytol (trade name: Feraheme), are being investigated off-label as USPIO contrast 
agents for MR imaging [99, 100].  
Cellular MRI has the capacity to track transplanted or endogenous cells with MPIO, 
SPIO, or USPIO depending on the cell labeling strategy that is used. In vivo cell labeling 
is achieved by systemic injection of iron oxide nanoparticles to primarily image 
endogenous immune cells due to their innate phagocytic activity. Cells can also be 
labeled in vitro and subsequently implanted into a host for imaging. Many cell types take 
up iron oxide nanoparticles in culture without intervention and can be iron-labeled by 
simple co-incubation [17, 73, 95, 96, 101, 102]. In cell types that are not innately 
phagocytic, internalization of iron nanoparticles may be improved using transfection 
agents, electroporation, or magnetofection [103-106].  
Iron-labeled cell tracking has been applied to a variety of cell types, including: stem cells, 
immune cells, cancer cells, pancreatic islets, and hepatocytes [17, 36, 37, 52, 96, 97, 102, 
103, 107-118]. Despite concerns about functional and phenotypic alterations that could 
prevent accurate recapitulation of normal and pathological processes, very few 
detrimental effects have been observed regarding iron-labeled cells at a wide range of 
iron-loadings. MPIO or SPIO labeling of cancer cells has no discernable effect on 
viability, in vitro proliferation, apoptosis, necrosis, or in vivo metastatic efficiency 
compared to unlabeled cells [17, 36, 52]. Similarly, SPIO labeling of human 
mesenchymal and hematopoietic stem cells has no significant short- or long-term effects 
on viability, proliferation, or differentiation to adipogenic and osteogenic lineages; 
however there may be some effect on chondrogenesis [103, 119]. Notably, Rohani et al. 
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reported that MPIO-labeling of dendritic cells affects activation and maturation, though 
no differences in viability were found [112].  
Relatively few groups have used MRI to track labeled cancer cells, compared to other 
cell types. This is because iron particles are diluted in the progeny of proliferative cells 
and therefore labeled cells become undetectable by MRI after repeated cell divisions. 
Foster et al. monitored the iron content in proliferating melanoma cells (B16F10) in vitro 
using inductively coupled plasma-mass spectroscopy and microscopy. They reported the 
disappearance of intracellular iron in cancer cells after 5 days; this represented 
approximately the 6th generation of daughter cells and suggested these progeny would be 
undetectable by MRI [36]. Economopoulos et al. found a similar pattern of dilution for 
breast cancer cells (MDA-MB-231) using flow cytometry and PPB staining; by 4 days 
post-labeling, less than 50% of cells retained detectable quantities of iron. Notably, 1-
2.5% of cells still remained labeled by day 10, which suggests they were non-
proliferative or slowly cycling [37]. Heyn and colleagues obtained comparable results in 
a brain metastatic breast cancer model (MDA-MB-231-BR) by investigating ex vivo brain 
tissue sections stained with PPB. They observed both iron-positive solitary cells and 
micro-metastases; however, large tumors did not reveal any regions with iron-positive 
staining, despite nearly 100% labeling efficiency at the time of cell injection [17].  
Heyn et al. were the first to show that cellular MRI had the sensitivity to detect single 
iron-labeled cancer cells upon initial arrest in the brain, which is important for tracking 
metastatic spread [17, 97]. Single cell detection was feasible despite the intrinsically low 
sensitivity of this imaging modality by exploiting the blooming artifact, which caused 15-
fold amplification in the representation of individual MPIO-labeled cancer cells. That is, 
cancer cells of approximately 20 µm in diameter created discrete signal voids that were 
300 µm wide in the MR image [17]. Moreover, the discrete signal voids detected in MRI 
could be co-registered with microscopy images that revealed the presence of solitary DiI-
labeled and green fluorescent cancer cells [17, 97].  
Cellular MRI technology has also been adapted to follow cancer cell fate in animal 
models over time. Heyn and colleagues monitored brain metastatic development over one 
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month in the MDA-MB-231-BR model [17]. Regions of signal void representing solitary 
and small clusters of iron-labeled cells were visible in the brain early after injection. 
After one-month surveillance, three distinct cell fates were discernable. Consistent with 
metastatic inefficiency, most cancer cells were ‘transient’ (93.9%); these signal voids 
were present after injection but disappeared over time. A small population of cells was 
‘proliferative’ (1.6%) and appeared as regions of signal void after injection that later 
grew into tumors at the same location. Finally, ‘non-proliferative’ cancer cells were also 
observed (4.5%) by virtue of long-term MPIO retention causing regions of persisting 
signal void in MR images and iron-positive cells in PPB-stained brain sections [17]. This 
subpopulation of non-proliferative cancer cells is thought to represent ‘quiescent’ or 
‘dormant’ cancer cells that are in reversible G0-G1 cell cycle arrest and may proliferate 
to form relevant metastases in the future. Illustration of cell fate surveillance using this 
technique is shown in Figure 1.5 where proliferative and non-proliferative cancer cells 
are co-detected in the mouse brain over time.  
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Figure 1.5: Visualization of cancer cell fate during metastatic development using 
cellular MRI.  Tracking MPIO-labeled MDA-MB-231-BR-HER2 cells in the mouse 
brain over time reveals distinct cancer subpopulations with different latency 
periods. After intracardiac injection (day 0), all cancer cells arresting in the brain 
appear similar as discrete regions of signal void. Over time, the iron label is diluted 
among proliferative cells and they are undetectable by MRI until a tumor forms in 
their place (white arrow). Slowly-cycling or non-proliferative cancer cells can be 
detected alongside proliferative cells and tumors due to their long-term retention of 
the iron label (black arrow). 
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The retention of iron by slowly-cycling or non-proliferative cancer cells has been 
exploited by some groups to monitor this unique cell population. Magnitsky et al. tracked 
slowly-cycling UPSIO, SPIO, and MPIO-labeled melanoma cells (WM3734) within the 
tumor mass using in vivo and ex vivo MRI. They found slowly-cycling iron-labeled cells 
often formed clusters nearby vasculature; interestingly, this observation was previously 
associated with cancer stem cells [115]. Consistent with this result, Economopoulos et al. 
also observed distinct zones of hypointensity due to clusters of iron-retaining non-
proliferative cancer cells within primary tumors (MDA-MB-231). Notably, this group 
also found regions of signal void within the lymph nodes and was the first to observe 
migration of metastatic iron-labeled cancer cells from a primary tumor [37].  
Cellular MRI has been useful to simultaneously monitor treatment response of both non-
proliferating iron-labeled cancer cells and macroscopic tumor burden. Townson et al. 
used this approach in a murine model of melanoma metastasis to the liver (B16F1) and 
reported heterogeneous response among metastatic cell populations to cytotoxic 
chemotherapy with doxorubicin [38]. The growth of metastasis was inhibited by 1 mg/kg 
doxorubicin administered three times weekly; however, the number of co-existing 
dormant cancer cells, as measured by signal void area, did not change after treatment 
[38]. Importantly, eradication of the tumor burden would have suggested complete and 
successful response to treatment, had cell tracking not revealed a substantial population 
of persisting cancer cells in MRI. Further investigation of the dormant cell population by 
cellular MRI is warranted; if these cells are viable and clonogenic, then they may play a 
critical role in treatment failure leading to recurrence.  
1.4 Treatment for Brain Metastasis 
In general, systemic chemo- and molecular anti-cancer therapies, which are highly 
successful at treating extra-cranial metastases, are ineffective for brain metastases 
because they are unable to cross the intact BBB/BTB in sufficient concentrations [10, 22-
24, 44]. This leaves few treatment options for brain metastases. The National 
Comprehensive Cancer Network published their consensus on clinical practice guidelines 
in oncology for CNS cancers, which included management strategies for brain metastases 
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[79]. Symptoms, such as headache, neurologic dysfunction, and seizures, can be managed 
with steroids and anti-epileptic drugs. Corticosteroids, such as dexamethasone, are used 
to reduce swelling in the brain and to help alleviate symptoms. This treatment alone 
offers survival of only 1 – 2 months [120]. Primary anti-cancer treatment possibilities to 
extend survival include: whole brain radiotherapy (WBRT), surgical resection, 
stereotactic radiosurgery (SRS), or some combination of these.  
WBRT is a mainstay in the treatment for brain metastasis; in this method, radiation dose 
is delivered to the entire brain volume, regardless of tumor location. It is often used as an 
adjuvant therapy, though it can be used alone for palliation.  WBRT alone improves 
neurologic symptoms and may extend survival to 4 – 6 months; however, recurrences in 
the brain after WBRT alone are common [121, 122].  
Surgical resection involves craniotomy followed by neurosurgery to remove or debulk 
the tumor mass. In 1990, Patchell and colleagues published results indicating that surgical 
resection followed by WBRT was superior to WBRT alone in a randomized trial 
including 48 patients with a solitary brain metastasis. In this study, the surgical group 
outlived the radiation group by more than 2.5 times and remained functionally 
independent nearly 5 times longer [123].  
In 1998, Patchell and colleagues published another randomized clinical trial comparing 
surgical resection alone versus surgical resection followed by WBRT and determined that 
adjuvant WBRT was beneficial for patients with a single metastasis, even when complete 
surgical resection of the tumor was achieved. Recurrence in the brain was reduced in the 
radiotherapy group and patients were less likely to die from neurologic causes than 
patients who underwent surgical resection alone [124].  
SRS offers an alternative and less invasive treatment option compared to surgery. This is 
beneficial for tumors that develop in eloquent cortical areas, which were previously 
considered untreatable due to potentially devastating neurological side effects from 
surgery. Furthermore, SRS is advantageous for treatment of deep-seated and otherwise 
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unresectable tumors [79]. This technique uses multiple convergent radiation beams to 
deliver very high radiation doses to a precise tumor volume.  
1.4.1 Oligometastatic Disease (1 – 3 metastases) 
Patients presenting with few metastatic lesions on MRI (typically 1 – 3) and controlled 
extra-cranial disease may undergo surgical resection [79]. Surgical excision of brain 
metastasis may also be indicated, regardless of systemic disease status, if the mass effect 
by the tumor causes significant symptoms for the patient. Tumor location and 
accessibility are critical factors for determining if surgical intervention is the most 
feasible and advantageous approach.  
Following resection, WBRT and/or SRS are used as adjuvant therapies to control 
micrometastatic disease in the surgical bed and surrounding brain tissue [79]. WBRT is 
delivered in radiation doses ranging from 20 – 40 Gy in 5 – 20 fractions, though 30Gy/10 
or 37.5Gy/15 are common treatment regimens [79, 125]. SRS typically uses single doses 
of 15-24 Gy [79]. In some cases, WBRT may be delivered in addition to a SRS ‘boost’ to 
the surgical bed.  
The primary treatment for patients with oligometastatic disease that is not amenable to 
surgery is WBRT and/or SRS. In the Radiation Therapy Oncology Group (RTOG 9508) 
clinical trial of patients with one to three brain metastases, Andrews and colleagues found 
that SRS in combination with WBRT improved survival when compared to WBRT alone 
but only in the subset of patients with single metastases or favorable features. In addition, 
patients who underwent SRS had better neurologic function six months post-treatment 
than those who had WBRT alone [126]. There is concern that WBRT leads to 
neurocognitive decline compared to SRS or surgical resection. Nevertheless, in the 
comparison of SRS or surgical resection of one to three brain metastases versus the same 
treatments followed by WBRT, the European Organization for Research and Treatment 
of Cancer (EORTC 22952-26001) study found that adding WBRT reduced recurrence of 
initial brain metastases and the development of new metastases but did not improve 
overall survival or functional decline [127].  
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If oligometastatic disease is presented with disseminated systemic disease, then WBRT 
followed by appropriate systemic therapy are used as primary treatment [79].  
1.4.2 Multiple Metastatic Lesions (>3 metastases) 
WBRT is the clinical standard for treating multiple (e.g. > 3) brain metastases and diffuse 
disease, though this treatment alone is generally considered palliative. Surgical resection 
may be considered to relieve mass effect [79]. In patients with unfavorable prognostic 
scores, supportive care only may be an option. 
1.4.3 Preventative Treatment 
Prophylactic cranial irradiation (PCI) is a preventative treatment for patients at high-risk 
of developing clinically relevant brain metastasis. It is a WBRT-like regimen that is 
employed if developing micro-metastatic foci are suspected in the brain, but are not yet 
detectable by radiology.  PCI decreased the subsequent incidence of brain metastasis in a 
study of 286 patients with extensive small-cell lung cancer (SCLC) responding to 
chemotherapy; moreover, PCI prolonged both disease-free and overall survival [128]. 
Despite the significant survival benefit in SCLC patients, PCI does not guarantee 
prevention of brain metastasis and may cause unwanted neurocognitive side effects. For 
this reason, the risk to benefit ratio for this method is not favorable in many other 
cancers. The utility of PCI is therefore mainly limited to SCLC patients, though it has 
been discussed for some patients with advanced metastatic breast cancer who develop 
brain metastasis at a high rate, such as those who are HER2+ [129].  
1.5 Purpose of Thesis 
This thesis uses MRI to monitor the development of brain metastasis due to HER2+ 
breast cancer and track cancer cells in mouse models over time. The objectives of this 
work were to use in vivo MR image techniques to characterize new models of brain 
metastasis due to HER2+ breast cancer and investigate how radiotherapy affected 
metastatic development, dormancy, and tumor permeability. 
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1.5.1 Hypotheses 
1.  There will be differences in tumor growth and morphology, as well as 
differences in MRI appearance, of brain metastasis resulting from each of 
the HER2+ breast cancer cell lines: SUM-190-BR3, JIMT-1-BR3, and 
MDA-MB-231-BR-HER2.   
2.  A modified micro-CT/RT system can be used to irradiate the whole mouse 
brain to a dose of 10 Gy per fraction in a reasonable treatment time. 
3.  WBRT, when delivered after tumor detection by MRI, will decrease the 
tumor burden and increase tumor permeability to Gd. 
4.  Early WBRT will halt the transition to growth from disseminated solitary 
cancer cells, but will not alter the number of non-proliferative cancer cells.   
In Chapter 2, high resolution anatomical and contrast-enhanced MRI was used to 
quantify tumor growth and BBB integrity in three experimental models of brain 
metastasis due to HER2+ breast cancer.  This work explores the relationship between 
tumor development and permeability as well as the heterogeneity present amongst animal 
models of the same disease. This chapter was published in Translational Oncology 
(Murrell DH et al., Understanding heterogeneity and permeability of brain metastases in 
murine models of HER2-positive breast cancer through magnetic resonance imaging: 
implications for detection and therapy Translational Oncology 2015 8(3):176-184). 
In Chapter 3, a micro-CT/RT system was commissioned for use in mouse brain 
irradiation. This was then employed to develop a clinically relevant WBRT plan to 
investigate the impact of radiation on brain metastasis development and BBB 
permeability in the MDA-MB-231-BR-HER2 model. This chapter was published in 
Translational Oncology (Murrell DH et al., Evaluating changes to blood-brain barrier 
integrity in brain metastasis over time and after radiation treatment Translational 
Oncology 2016 9(3): 219-227). 
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In Chapter 4, the micro-CT/RT system and mouse WBRT plan were used to investigate 
the impact of early radiation treatment on brain metastasis development and dormancy in 
the MDA-MB-231-BR-HER2 model. This chapter is under review in Radiotherapy and 
Oncology (Murrell DH et al., MRI surveillance of cancer cell fate in a brain metastasis 
model after early radiotherapy Radiotherapy and Oncology).   
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Chapter 2  
2 Understanding Heterogeneity and Permeability of Brain 
Metastases in Murine Models of HER2-positive Breast 
Cancer through Magnetic Resonance Imaging: 
Implications for Detection and Therapy 
Objectives: Brain metastases due to breast cancer are increasing and the prognosis is 
poor. Lack of effective therapy is attributed to heterogeneity of breast cancers and their 
resulting metastases, as well as impermeability of the blood-brain barrier (BBB), which 
hinders delivery of therapeutics to the brain. This work investigates three experimental 
models of HER2+ breast cancer brain metastasis to better understand the inherent 
heterogeneity of the disease. We use MRI to quantify brain metastatic growth and explore 
its relationship with BBB permeability. Methods: Brain metastases due to breast cancer 
cells (SUM190-BR3, JIMT-1-BR3, or MDA-MB-231-BR-HER2) were imaged at 3T 
using balanced steady state free precession (bSSFP) and contrast-enhanced T1-weighted 
spin echo sequences. The histology and immunohistochemistry corresponding to MRI 
was also analyzed. Results: There were differences in metastatic tumor appearance by 
MRI, histology, and immunohistochemistry (Ki67, CD31, CD105) across the three 
models. The mean volume of a MDA-MB-231-BR-HER2 tumor was significantly larger 
compared to other models [F(2,12)=5.845, p <0.05]; interestingly, this model also had a 
significantly higher proportion of Gd-impermeable tumors [F(2,12)=22.18, p < 0.0001]. 
Ki67 staining indicated that Gd-impermeable tumors had significantly more proliferative 
nuclei compared to Gd-permeable tumors [t(24)=2.389, p<0.05] in the MDA-MB-231-
BR-HER2 model. CD31 and CD105 staining suggested no difference in new vasculature 
patterns between permeable and impermeable tumors in any model. Conclusions: 
Significant heterogeneity is present in these models of brain metastases from HER2+ 
breast cancer. Understanding this heterogeneity, especially as it relates to BBB 
permeability, is important for improvement in brain metastasis detection and treatment 
delivery.  
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2.1 Introduction 
Breast cancer will affect approximately 1 in 8 American women [1]. It is the most 
commonly diagnosed cancer in women and is the second leading cause of cancer death in 
American women [1]. The major challenge of this disease is its propensity to metastasize 
to distant sites such as bone, liver, lung, and brain [2]. The relative rate of breast cancer 
brain metastasis is extremely high, second only to lung cancer [3].  
Breast cancer is a complex and heterogeneous disease and is classified into at least four 
molecular subtypes with different prognostic significance; further classification exists by 
histological type and grade [2, 4, 5]. No single subgroup is biologically homogeneous. 
The HER2 subtype – estrogen receptor negative (ER-), progesterone receptor negative 
(PR-), HER2+ [6] – is of particular concern since it accounts for 10-15% of breast 
cancers and develops brain metastases at a significantly higher rate compared to other 
breast cancer subtypes [2, 7]. 
Brain metastases that form from breast cancers are also complex and heterogeneous. 
These can manifest in three clinically distinct situations: multiple brain metastases (78%), 
solitary brain metastasis (14%), or leptomeningeal metastasis (8%) [8].  Each 
manifestation dictates a different course of treatment; however, responses to therapy vary 
among metastases. Some metastases will not respond to therapy while others will appear 
to initially respond, but develop resistance during treatment, or will cause recurrence at a 
later time. This heterogeneity in tumor response complicates clinical management and 
contributes to the poor prognosis for this disease.  
Clinical data suggest that HER2 overexpression is present in as many as 53% of breast 
cancer brain metastasis cases [7]. Median survival from diagnosis of HER2+ brain 
metastases to death is 4-6 months and less than 20% of patients can expect to live one 
year [9].  Treatment for HER2+ metastatic breast cancer includes anti-HER2 therapy 
such as trastuzumab (Herceptin ®). Despite improvement in both disease-free and overall 
survival [10], CNS metastases develop in 31-48% of patients on trastuzumab [11-14] and 
33-50% of those are responding to therapy or have stable disease at other sites when 
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diagnosed with CNS involvement [11, 14]. This suggests that the brain offers a sanctuary 
site where metastases can persist, unaffected by therapy.  
The poor prognosis for brain metastases has been largely attributed to obstacles created 
by the BBB. Under normal conditions, the BBB acts to protect the brain by tightly 
regulating the diffusion of substrates from the blood into the brain parenchyma [15]; 
however this also causes systemic therapies to be excluded from the brain. For example, 
chemo- and targeted therapies – such as doxorubicin and trastuzumab – which are highly 
successful at treating HER2+ metastases in other areas of the body, are ineffective for 
brain metastases [14, 16] presumably because they are unable to cross the intact BBB. 
Studying brain metastatic breast cancer is challenging because there are few experimental 
animal models [17-20].  The MDA-MB-231-BR cell line has been the most widely used 
to study brain metastasis from breast cancer [18, 21-29]. Work performed in the Steeg 
laboratory has shown that this preclinical model shares many characteristics of human 
brain metastases [22]. The MDA-MB-231-BR cell line has also been transduced with 
HER2 cDNA (resulting in the MDA-MB-231-BR-HER2 cell line) and significant 
heterogeneity in the permeability of the BBB associated with these brain metastases was 
demonstrated by Lockman et al. using dextran perfusion and ex vivo fluorescence 
microscopy [30]. 
Imaging is increasingly being used to study models of brain metastasis. MRI allows for 
non-invasive, three-dimensional, longitudinal studies at very high spatial resolution and a 
wide range of contrast mechanisms are possible. Contrast-enhanced T1-weighted (T1w) 
MRI, which relies on tumor detection by diffusion of Gd across an impaired BBB in the 
local region of a tumor, is widely regarded as the most accurate method for clinical brain 
tumor detection.  A previous imaging study performed in our laboratory showed that not 
all 231BR brain metastases were detectable after Gd-enhanced MRI and that the BBB 
permeability changed over time as brain metastases developed [24]. These findings 
suggest that brain metastases that are not permeable to Gd may go undetected by 
conventional MRI.  In addition, heterogeneity in BBB permeability between metastases 
also means that therapeutic access to individual brain metastases varies [28, 30, 31]. 
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In this study we explore the relationship between the growth of brain metastases and their 
permeability status in three HER2+ human brain metastatic breast cancer cell lines, two 
of which are HER2 expressing cell lines that have been recently developed. We present 
quantification of metastasis volume in the whole mouse brain using high resolution 3D 
MRI, as well as an assessment of the integrity of the BBB associated with each tumor 
(BTB). Correlative histology and immunohistochemistry provide image validation and 
further characterization of each cell line.  
2.2 Methods 
2.2.1 Cell Culture 
The following three HER2+ human brain metastatic breast cancer cell lines were used: 
(1) MDA-MB-231-BR-HER2 [19], (2) JIMT-1-BR3 [32], (3) SUM190-BR3. The MDA-
MB-231-BR-HER2 cell line is derived from the breast carcinoma parental line, MDA-
MB-231, and transfected with HER2 [19]; the other two cell lines were derived from 
their parental lines – JIMT-1 [20] and SUM190 [33] respectively – and are HER2+. All 
three cells line were developed in the lab of Dr. Patricia Steeg at the National Cancer 
Institute (Bethesda, MA).  For MDA-MB-231-BR-HER2 and JIMT-1-BR3, cells were 
maintained in Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum. MDA-
MB-231-BR-HER2 media also contained penicillin and streptomycin; the JIMT-1-BR3 
media contained 2mM glutamine. SUM190-BR3 cells were grown in serum-free Ham’s 
F-12 medium supplemented with insulin and hydrocortisone. Culture media and 
supplements were purchased from Thermo Fisher Scientific (Mississauga, ON). All cell 
lines were maintained at 37°C and 5% CO2. Cell viability was calculated by the trypan 
blue exclusion assay. 
2.2.2 Cell Labeling 
For a subset of in vivo experiments, cells were labeled with micron-sized iron oxide 
particles (0.9 µm MPIO, Bangs Laboratory, Fishers, IN) for cell tracking by MRI as 
previously described [21]. Labeling was achieved by co-incubating 2x106 seeded cells 
with MPIO at a concentration of 25 µg Fe/mL for 24 hours in a T75cm2 flask. The cells 
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were harvested and thoroughly washed three times with Hank’s Balanced Salt Solution 
(HBSS) in order to remove unincorporated MPIO prior to cell injection. Perl’s Prussian 
Blue (PPB) stained cytospin slides were analyzed to determine labeling efficiency; this 
was calculated in ImageJ software (Open-source, NIH, USA) as the ratio of PPB-positive 
cells to the total number of cells in five random fields of view at 40x magnification using 
a Zeiss AXIO Imager A1 Microscope.  
Iron-labeled cells create regions of signal void on MR images [21, 23] and allow for the 
confirmation of successful cell injections and arrest of cancer cells in the brain; lack of 
signal voids results in exclusion from further study. 
2.2.3 Animal Preparation 
Female nude mice (nu/nu, aged 6-8 weeks from Charles River Laboratories, Wilmington, 
MA) were housed in a pathogen-free barrier facility and all experiments were approved 
by the Animal Use Subcommittee of the University Council on Animal Care at the 
University of Western Ontario. Cells suspended in 0.1mL of Hank’s balanced salt 
solution were delivered to female nude mice, anesthetized with 2% isoflurane in oxygen, 
by intracardiac injection to the beating left ventricle of the mouse heart.  
The three brain metastatic breast cancer models were injected intracardially into mice. 
The first group (n=5) was injected with 100,000 MDA-MB-231-BR-HER2 cells per 
mouse; another group of mice (n=6) was injected with 175,000 JIMT-1-BR3 cells; the 
final group (n=4) was injected with 500,000 SUM190-BR3 cells. The number of injected 
cells was selected based on in vivo tumorgenic potential determined from previous 
studies [28]. 
2.2.4 Experimental Endpoint 
Mice were scanned using MRI at the experimental endpoint and then euthanized by an 
overdose injection of pentobarbital (Euthanyl). The endpoint was determined by the onset 
of neurological symptoms, unacceptable weight loss and body condition, or hind-limb 
paralysis. Different degrees of in vivo tumor growth and aggressiveness caused the 
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endpoint to be reached at different times for each model; this is further discussed in our 
results. The endpoints were day 28 for JIMT1-BR3, day 36 for MDA-MB-231-BR-HER2 
and day 64 for SUM190-BR3. 
2.2.5 Magnetic Resonance Imaging 
All images were acquired on a 3.0T GE MR750 clinical scanner (General Electric, 
Mississauga, Canada), using a custom-built insertable gradient coil (inner diameter = 
17.5cm, gradient strength = 500 mT/m, and peak slew rate = 3000 T/m/s) and a custom 
solenoidal mouse head radiofrequency (RF) coil (inner diameter = 1.5cm). Mice were 
anesthetized (1.5% isoflurane in oxygen) and temperature was maintained using warm 
saline bags during the scans. In vivo MRI was acquired using two pulse sequences: a 
three-dimensional bSSFP scan, and a two-dimensional post-Gd T1-weighted spin echo 
(T1wSE) scan.  
The bSSFP sequence was used to detect signal voids post-cell injection on day 0, and to 
quantify metastases numbers and volumes in the whole mouse brain. The parameters for 
the bSSFP scans were as follows: resolution = 100 x 100 x 200 µm, repetition time = 8 or 
10 ms, echo time = 4 or 5ms, flip angle = 35°, signal averages = 2, RF phase cycles = 8, 
scan time = 28 or 36 minutes. The T1wSE was acquired approximately 40 minutes after 
the intraperitoneal (ip) administration of 0.2mL gadopentetate dimeglumine (Magnevist, 
Schering, US; 0.5 mmol/mL) and used to assess the BTB associated with individual 
tumors. The parameters for these scans were as follows: resolution = 156 x 156 x 400 
µm, repetition time = 600 ms, echo time = 20 ms, signal averages = 8, scan time = 20 
minutes. Zero filling interpolation (ZIP) was applied to all images. 
2.2.6 Histology and Immunohistochemistry 
At respective endpoints, all mice were sacrificed by pentobarbital overdose and perfused 
with saline and subsequently with 4% paraformaldehyde or 4% formalin.  Brains were 
excised and placed in paraformaldehyde for at least another 24h.  Fixed brains were 
processed, paraffin-embedded and serially cut into 5 µm sections. Tissue sections were 
deparaffinized, rehydrated and either histologically stained with hematoxylin and eosin 
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(H&E) or stained for CD31, CD105 or ki67 by immunohistochemistry. Heat mediated 
antigen retrieval with citrate buffer pH6 was performed for sections that were to be 
stained for CD31 or Ki67. All tissue sections were blocked with Dako protein block, 
serum free (Dako Canada, Inc, Burlington, ON, Canada) and the following rabbit 
polyclonal antibodies were used: anti-CD31 (1:50, ab28364, Abcam Inc, Toronto, ON, 
Canada), anti-CD105 (1:1000, ab107595, Abcam Inc), anti-Ki67 (1:100, ab833, Abcam 
Inc). Dako LSAB2 system-HRP (Dako Canada Inc) and Vector DAB peroxidase 
substrate kit (Vector Laboratories, Burlingame, CA, USA) were used according to 
manufacturers’ instructions to detect positive staining.  All stained sections were 
counterstained with hematoxylin before dehydration and mounting.  All staining was 
imaged on an Axio Imager A1 microscope (Zeiss CANADA, Toronto, ON, Canada) with 
a Retiga EXi (QImaging Scientific Research Cameras, Surrey, BC, Canada) digital 
camera. 
2.2.7 Data Analysis 
Images were analyzed using open-source OsiriX image software, version 3.9.2. 
Qualitative analysis of signal voids on day 0 confirmed mice with successful iron-labeled 
cell injections; lack of signal voids excluded mice from further study. Brain metastases 
were counted manually. 3D tumor volumes were reconstructed using the OsiriX volume 
algorithm from the manual segmentation of a ROI around each tumor boundary in every 
bSSFP image slice for each mouse. Comparison of corresponding bSSFP and T1wSE 
images were used to qualitatively assess BTB permeability to Gd – if metastases were 
detected on the T1wSE, these were classified as “Gd-permeable”; in contrast, if they 
were detected on the bSSFP but not in the corresponding T1wSE, these were deemed 
“Gd-impermeable”. If corresponding images were not available, permeability status was 
not decided. The “Gd-permeable fraction” was determined as the percentage of Gd-
permeable metastases in relation to the total number of metastases in the whole brain at a 
specific time point. To evaluate the proliferative index of Gd-permeable and Gd-
impermeable tumors, Ki67 stained tissue sections were matched to MRI data and imaged 
at 40x magnification; all nuclei within a random field of view in the tumor were manually 
counted. The proliferative index was calculated as the percent of Ki67-positively stained 
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nuclei among all MDA-MB-231-BR-HER2 cancer cells. All values are presented 
graphically as mean ± SE. Statistical analysis was performed using unpaired t-tests, or a 
one-way analysis of variance followed by Tukey Honestly Significant Difference tests on 
GraphPad Prism version 6 software (GraphPad, San Diego, CA).  
2.3 Results 
Representative images of brain metastases from each group are shown in Figure 2.1. 
Contrast in bSSFP images is related to the ratio of spin-spin to spin-lattice relaxations 
(T2/T1); in general, metastases appear hyperintense compared to brain parenchyma due 
to relatively higher fluid content and therefore a longer T2 and T2/T1 ratio.   
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Figure 2.1: Representative images showing metastases resulting from SUM190-BR3, 
JIMT-1-BR3, or MDA-MB-231-BR-HER2 human brain metastatic breast cancer.  
(A-C) bSSFP images show metastasis burden (hyperintensities); (D-F) correlative 
H&E stained sections of the area indicated by boxes shows morphology of tumors in 
each model; (G-I) Ki67 staining indicates proliferative nuclei in brown. The region 
of signal void in the center of the SUM190-BR3 tumor (A) relates to the necrotic 
core seen in histology (D). JIMT-1-BR3 tumors are hyperintense in bSSFP (B) and 
grow as dense and proliferative nuclei clusters (E,H). 231-BR-HER2 tumors are the 
most hyperintense in bSSFP (C) and present as clusters of highly proliferative cell 
nuclei within pockets of edema in H&E (F,I). 
  
  
 
61 
The three models of HER2+ breast cancer brain metastasis each had a different 
appearance by MRI as well as in histology and immunohistochemistry. The SUM190-
BR3 tumors were hyperintense with a hypointense core in bSSFP images (Figure 2.1A); 
this appearance was reflected in the corresponding H&E and Ki67 stained tissue sections 
where a necrotic core was evident (Figure 2.1D) and proliferation was evident around the 
outer edge (Figure 2.1G). The JIMT-1-BR3 tumors also appeared hyperintense in bSSFP 
images (Figure 2.1B) and tissue staining showed tumors with dense clusters of 
proliferative nuclei (Figure 2.1E,H). The MDA-MB-231-BR-HER2 tumors appeared the 
brightest in bSSFP images (Figure 2.1C). In H&E stained sections they present as small, 
dense clusters of cell nuclei surrounded by substantial pockets of edema (Figure 2.1F); 
Ki67 staining indicated these tumors were highly proliferative (Figure 2.1I).  
The 3D high-resolution nature of MRI allowed us to quantify metastasis volume and 
permeability in the whole mouse brain for each animal in all three models. We evaluated 
198 tumors at experimental endpoint across the three models. Tumor incidence and total 
tumor burden are shown in Table 2.1. The SUM190-BR3 model grew few tumors and the 
total tumor volume per brain was relatively low despite having the most cells injected. 
The MDA-MB-231-BR-HER2 model was injected with the least cells, yet grew the most 
tumors and had the highest total tumor volume. The study endpoint was decided when 
mice displayed clinical symptoms of the disease and deteriorating health. The time to 
endpoint was different for each model – day 28 for JIMT-1-BR3, day 36 for MDA-MB-
231-BR-HER2, and day 64 for SUM190-BR3. The mean volume of each tumor was 
calculated at these times for all mice in each of the three models  (Figure 2.2). The 
average volume of a tumor was significantly different between models [F(2,12)=5.845, 
p<0.05], but interestingly a longer experiment did not mean larger tumors. Post hoc 
Tukey tests showed that MDA-MB-231-BR-HER2 tumors were significantly larger in 
size compared to JIMT-1-BR3 or SUM190-BR3 tumors, despite the fact that the 
SUM190-BR3 model grew for longer. No significant difference in tumor volume was 
observed between JIMT-1-BR3 and SUM190-BR3 models, yet the SUM190-BR3 model 
grew for more than twice as long before the mice were noted to have neurological 
symptoms.   
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Table 2.1: Tumor incidence and burden at endpoint for each brain metastasis 
model. Number of tumors and total tumor volume is shown for each mouse, as well 
as average values and standard deviations within each model. Overall, SUM190-
BR3 mice have the smallest tumor burden, and MDA-MB-231-BR-HER2 mice have 
the largest, both in terms of number of tumors and total tumor volume. 
SUM190-BR3 
500,000 cells injected 
JIMT-1-BR3 
175,000 cells injected 
231-BR-HER2 
100,000 cells injected 
Mouse 
ID 
# of 
Tumors 
Total 
Tumor 
Volume 
(mm3) 
Mouse 
ID 
# of 
Tumors 
Total 
Tumor 
Volume 
(mm3) 
Mouse 
ID 
# of 
Tumors 
Total 
Tumor 
Volume 
(mm3) 
1 
7 
8 
19 
1 
1 
2 
1 
0.09 
0.17 
0.65 
0.17 
9 
10 
12 
13 
15 
17 
28 
26 
20 
5 
8 
4 
5.4 
7.6 
2.8 
1.5 
1.1 
0.67 
1 
2 
3 
4 
5 
9 
11 
54 
21 
7 
1.7 
11 
31 
7.3 
4.7 
Mean 1 .25 0.2 Mean 15 3 Mean 20  11 
SD ± 0.5 0.3 SD ± 11 3 SD ± 20 12 
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Figure 2.2: Quantification of mean volume per tumor (±SEM) at endpoint in 
SUM190-BR3, JIMT-1-BR3 and MDA-MB-231-BR-HER2 models. The average 
volume of a tumor was significantly different between groups [F(2,12)=5.845, 
p<0.05] and MDA-MB-231-BR-HER2 tumors were significantly larger in size 
compared to JIMT-1-BR3 or SUM190-BR3 tumors. No other significant differences 
were observed. 
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The tumor permeability status for the three models is shown in Figure 2.3. A significant 
difference was observed in the percentage of Gd-permeable, or Gd-impermeable tumors 
between models [F(2,12)=22.18, p<0.0001]. Post hoc Tukey tests showed the MDA-MB-
231-BR-HER2 had a significantly different proportion of Gd-permeable and Gd-
impermeable tumors compared to the JIMT-1-BR3 or SUM190-BR3 models. All of the 
SUM-190-BR3 tumors and most JIMT-1-BR3 tumors were Gd-permeable, whereas only 
63.6% of the MDA-MB-231-BR-HER2 tumors displayed BTB permeability to Gd. T1w 
SE post-Gd MR failed to detect 36.4% of MDA-MB-231-BR-HER2 metastases that were 
visible in bSSFP images. No other significant differences within or between groups were 
observed.  
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Figure 2.3: Quantification of the mean percentage of Gd-permeable (black) and Gd-
permeable (white) tumors (±SEM).  The percentage of Gd-permeable, or Gd-
impermeable tumors was significantly different between groups [F(2,12)=22.18, 
p<0.0001]. All SUM190-BR3 and most JIMT-1-BR3 tumors were Gd-permeable, 
whereas only 63.6% of MDA-MB-231-BR-HER2 tumors display BTB permeability 
to Gd. Post hoc Tukey tests showed the MDA-MB-231-BR-HER2 had a significantly 
different proportion of Gd-permeable and Gd-impermeable tumors compared to 
the JIMT-1-BR3 or SUM190-BR3 models.  No other significant differences in 
permeability were observed. 
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Figure 2.4 shows representative bSSFP and T1w post Gd images for a mouse with MDA-
MB-231-BR-HER2 brain metastases. Three metastases were evident in the bSSFP image, 
yet only two of these were detectable in the T1wSE post-Gd. This suggested that the BTB 
associated with the third metastasis was intact.   
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Figure 2.4: In vivo visualization of heterogeneous BTB permeability in the same 
animal.  Axial MR images of the mouse brain; tumor burden is shown in the bSSFP 
image (left) and BTB permeability associated with the tumors is indicated in the 
T1w SE post-Gd (right). Three tumors are visualized in the bSSFP image, yet only 
two are detectable in the T1w SE post-Gd. This suggests that Gd cannot cross the 
BTB associated with tumor 3 and demonstrates the difference in tumor detection 
using contrast-enhanced MRI compared to the bSSFP sequence. 
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Immunohistochemistry was performed and evaluated, including CD31, CD105 and Ki67 
stains, in an effort to understand factors that might relate to differences between Gd-
permeable and Gd-impermeable tumors. Individual tumors in whole brain sections were 
identified as either Gd-permeable or Gd-impermeable by comparing to MRI. For this 
analysis, Gd-impermeable tumors were assessed only from the MDA-MB-231-BR-HER2 
model, due to their low prevalence in the other models. Ki67 is a marker for proliferative 
nuclei and was used to calculate the mean proliferative index for Gd-permeable and Gd-
impermeable brain metastases in the MDA-MB-231-BR-HER2 model. The proliferative 
index was determined as the percentage of positively stained nuclei among MDA-MB-
231-BR-HER2 cells. The proliferative index for Gd-impermeable tumors was 
significantly higher than for Gd-permeable tumors [t(24)=2.389, p<0.05] (Figure 2.5).   
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Figure 2.5: The mean proliferation index (±SEM) for Gd-permeable and Gd-
impermeable brain metastases in the MDA-MB-231-BR-HER2 model.  This 
quantifies tumor proliferation by Ki67 staining and indicates there is a significantly 
more proliferative nuclei in Gd-impermeable compared to Gd-permeable brain 
metastases [t(24)=2.389, p<0.05]. 
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CD31 is a marker for endothelial cells and CD105 marks proliferative endothelial cells. 
Together, these stains visualize vasculature patterns and can indicate where new vessels 
are being formed. This staining was only assessed qualitatively and it is interesting to 
note the different staining patterns across the three models. In the SUM190-BR3 model, 
CD31 staining was strongly localized to the outer edge of the tumor rim whereas CD105 
staining was strongest on the inner edge of the tumor rim. This indicated the presence of 
vasculature around the tumor and new vasculature development inside, near the tumor 
core. The JIMT-1-BR3 and MDA-MB-231-BR-HER2 models had more similar patterns 
of CD31 and CD105 staining; the JIMT-1-BR3 model had existing and new vasculature 
dispersed throughout the tumor space while in MDA-MB-231-BR-HER2 tumors this 
appeared to be associated near areas of edema. Despite variance in vasculature patterns 
across the three models, no differences were observed between Gd-permeable and Gd-
impermeable tumors (Figure 2.6). 
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Figure 2.6: Representative images of CD31 (top) and CD105 (bottom) staining in 
SUM190-BR3, JIMT-1-BR3, and MDA-MB-231-BR-HER2 models.  Staining 
patterns were qualitatively assessed for the distribution of endothelial cells and 
proliferative endothelial cells in tumor regions. Different staining patterns are 
evident between models; however, there is no obvious difference in the staining 
patterns between Gd-permeable and Gd-impermeable metastases within the MDA-
MB-231-BR-HER2 model.   
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2.4 Discussion  
In vivo MRI is a valuable tool for preclinical investigation of brain metastatic breast 
cancer and associated tumor permeability. In the current work, we used MRI to compare 
HER2+ brain metastases from the following three human breast cancer cell lines: (1) 
MDA-MB-231-BR-HER2 [19]; (2) JIMT-1-BR3 [32]; (3) SUM190-BR3. We show that 
there are differences in MRI appearance and permeability to Gd in three different types of 
HER2+ brain metastases. Furthermore, there is significant heterogeneity of this disease, 
which is reflected by marked differences in the tumor incidence, total tumor burden, and 
average size of a tumor in each of these models.  
Our Gd-permeability analysis suggests that in vivo tumor permeability to Gd cannot be 
explained by lesion size, aggressiveness, or growth duration. Permeability to Gd indicates 
a disruption in the BBB, or BTB, when assessing brain tumors; this is important to 
understand because BBB disruption affects our ability to detect and treat brain 
metastases. Interestingly, models with smaller tumors – SUM190-BR3 and JIMT-1-BR3 
– had significantly higher proportions of Gd-permeable tumors than the MDA-MB-231-
BR-HER2 model, which had many Gd-impermeable metastases despite forming much 
larger metastases more quickly than the other models. Moreover, qualitative analysis of 
staining for endothelial cells (CD31) and proliferative endothelial cells (CD105) shows 
different vasculature patterns across different models of HER2+ brain metastatic breast 
cancer, but suggests no difference in development of new vasculature among Gd-
permeable compared to Gd-impermeable tumors.  This contradicts the dogma that large 
tumors have more neovasculature and are more ‘leaky’ [24, 34-36]. In addition to size, 
tumor aggressiveness does not explain permeability. Indeed, Gd-impermeable tumors in 
the MDA-MB-231-BR-HER2 model exhibited a significantly higher proliferative index 
than Gd-permeable tumors.  
Our results align with preclinical studies by Lockman et al. [30] and Percy et al. [24] who 
have also demonstrated heterogeneity in the permeability status associated with brain 
metastases. Varying levels of passive permeability to Texas Red Dextran (3 kDa) or 14C-
AIB (103 Da) were detected in MDA-MB-231-BR-HER2 metastases using ex vivo 
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fluorescence microscopy or autoradiography and it was found tumor permeability was 
not correlated with tumor size; in addition they suggest it is also unrelated to morphology 
or vascular density [30]. Percy et al. previously used the same in vivo MR imaging 
strategy used in our study and found Gd-permeable tumors were significantly larger than 
Gd-impermeable in the MDA-MB-231-BR model; however size alone was not sufficient 
to predict permeability [24]. Our work supplements these findings and further illustrates 
that tumor size and permeability are not directly related because models with smaller 
tumor size had higher proportions of Gd-permeable metastases. We demonstrate that 
tumor permeability is not the same in all models of HER2+ brain metastatic breast 
cancer.  
The difference in permeability status across and within the models raises two important 
clinical implications. First, systemic therapies may be ineffective because they rely on 
diffusion of a therapeutic across an impaired BBB for delivery to metastases. 
Trastuzumab is part of the standard treatment for HER2+ metastatic breast cancer; 
however, this molecule does not adequately cross the BBB [37] and is ineffective for 
brain metastatic breast cancer [11, 12]. Interestingly, our study shows almost all 
SUM190-BR3 and JIMT-1-BR3 tumors are permeable to Gd. This molecule is much 
smaller (590Da) than trastuzumab (145kDa) and therefore may cross the BBB where size 
restrictions would exclude trastuzumab. Secondly, and perhaps more important is the fact 
that the population of potentially unresponsive metastases, due to limited drug uptake, are 
also not likely to be detected by current Gd-enhanced imaging strategies.  
Importantly, it is possible for brain metastases to develop while maintaining an intact 
BBB. This may happen when tumors co-opt the pre-existing rich vasculature of the brain 
and develop alongside pre-existing microvessels [41-43]. In this situation, a large brain 
metastasis can develop with an intact BTB because the tumor grows around a pre-formed 
and properly constructed blood vessel. These tumors are radiographically invisible by 
Gd-enhanced MRI [41] because Gd does not extravasate from the intact blood vessel; 
however they are easily detectable in bSSFP images.  The bSSFP sequence is 
advantageous to detect ‘Gd-impermeable’ tumors because it offers high spatial resolution 
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and contrast is related to the ratio of spin-spin to spin-lattice relaxations (T2/T1) – rather 
than extravasation of a contrast agent. This allows for the visualization of all brain 
metastases – regardless of the degree of BBB permeability. The bSSFP pulse sequence is 
available on clinical MRI systems, but has been predominantly used for cardiac 
applications [38]. Further investigation of this pulse sequence for brain metastatic 
evaluation is warranted to determine its clinical utility. 
High-resolution MRI also allowed us to quantify the number and volume of metastases in 
the whole brain for every mouse in each model. We found marked differences in tumor 
incidence, total tumor burden, and appearance of metastases across the three models, 
despite the fact they are all meant to represent HER2+ brain metastatic breast cancer. The 
mean volume of MDA-MB-231-BR-HER2 metastases at endpoint was significantly 
larger than metastases in the JIMT-1-BR3 and SUM190-BR3 models. It is important to 
also consider the endpoint for each model to keep this result in context. The MDA-MB-
231-BR-HER2 model is the most aggressive; it grows many large tumors, despite the 
least number of cells injected, and has a relatively short timeline with endpoint typically 
required by day 36. In comparison, the JIMT-1-BR3 model has a lesser tumor burden, 
grows significantly smaller metastases, yet endpoint is reached earlier at day 27/28. The 
SUM190-BR3 model grows tumors similar in size to the JIMT-1-BR3 model, but the 
total tumor burden is small and these animals can survive more than twice as long, to day 
64. 
In summary, the differences in appearance, number, volume, and permeability across the 
three models highlight significant heterogeneity in HER2+ brain metastatic breast cancer. 
Our findings have implications for both preclinical and clinical understanding of this 
disease. It is important to study new diagnostics and therapeutics in animal models that 
accurately reflect human disease and the heterogeneity presented here suggests a panel of 
different models may be necessary to adequately accomplish this. From a clinical 
standpoint, understanding the heterogeneity presented in this work will be important for 
improvements in detection strategies and delivery of therapeutic agents. This work 
emphasizes the need for personalized medicine; for example, if a patient has brain 
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metastases similar to the 231-BR-HER2 model, it could be assumed MRI is ‘blind’ to 
approximately one third of the total brain metastatic burden present in that patient and 
systemic therapies may not be effective against a large proportion of their disease; other 
treatment avenues, such as radiotherapy, might be pursued in this case.  
3D MRI is a powerful tool to provide an in vivo comprehensive analysis of tumor 
incidence, tumor burden, and permeability status in preclinical models of HER2+ brain 
metastatic breast cancer. This information is challenging to obtain solely with ex vivo 
methods such as histology and immunohistochemistry, but it is important for 
understanding the natural heterogeneity present in experimental brain metastasis models. 
Understanding the disease heterogeneity presented here will be important for 
advancements in cancer diagnostics and therapy, and for improving patient management 
and survival.  
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Chapter 3  
3 Evaluating changes to blood-brain barrier integrity in 
brain metastasis over time and after radiation treatment 
Introduction: The incidence of brain metastasis due to breast cancer is increasing and 
prognosis is poor. Treatment is challenging because the blood-brain barrier (BBB) limits 
efficacy of systemic therapies.  In this work, we develop a clinically relevant whole brain 
radiotherapy (WBRT) plan to investigate the impact of radiation on brain metastasis 
development and BBB permeability in a murine model. We hypothesize that radiotherapy 
will decrease tumor burden and increase tumor permeability, which could offer a 
mechanism to increase drug uptake in brain metastases. Methods: Contrast-enhanced 
MRI and high resolution anatomical MRI was used to evaluate BBB integrity associated 
with brain metastases due to breast cancer in the MDA-MB-231-BR-HER2 model during 
their natural development. Novel image-guided micro-irradiation technology was 
employed to develop WBRT treatment plans and to investigate if this altered brain 
metastatic growth or permeability. Histology and immunohistochemistry was performed 
on whole brain slices corresponding with MRI to validate and further investigate 
radiological findings. Results: Herein, we show successful implementation of mirco-
irradiation technology that can deliver WBRT to small animals. We further report WBRT 
following diagnosis of brain metastasis can mitigate, but not eliminate, tumor growth in 
the MDA-MB-231-BR-HER2 model. Moreover, radiotherapy did not impact BBB 
permeability associated with metastases. Conclusions: Clinically relevant WBRT is not 
curative when delivered after MRI-detectable tumors have developed in this model. A 
dose of 20 Gy/2 was not sufficient to increase tumor permeability such that it could be 
used as a method to increase systemic drug uptake in brain metastasis. 
3.1 Introduction 
The relative five-year survival for breast cancer patients has steadily increased and was 
recently reported at 90% in the United States [1].  Now, the major challenge of this 
disease is its ability to metastasize to distant sites where detection and therapy become 
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complicated. The incidence of metastasis to the brain is especially high for women with 
breast cancer that overexpresses HER2 and has been reported at 25 – 48 % [2–4]. More 
concerning is that brain metastases often manifest while metastases outside of the brain 
are still responding to successful anti-HER2 therapies, such as trastuzumab (Herceptin®). 
Several factors may be involved in this type of mixed response, including: the unique 
microenvironment of the brain, neuro-inflammation, and genetic alterations distinct from 
the primary tumor [5, 6]. Notably, the inability of traditional systemic therapies to 
penetrate the intact BBB to any significant degree, or at all, presents a significant obstacle 
for drug delivery, thus rendering the brain a sanctuary site for metastatic growth [7, 8]. 
In the absence of effective systemic therapy, treatment options for patients with brain 
metastases are limited; they include steroids, surgical excision of solitary metastases, 
SRS for small lesions not amenable to surgery, and WBRT. While combinations of these 
options has improved prognosis, the median survival time of patients with HER2+ breast 
cancer is only 11.5-16.5 months after diagnosis of brain metastasis [9]. The clinical 
standard for treating multiple (e.g. > 3 lesions detected by MRI) brain metastases and 
diffuse disease is WBRT; however, this treatment is palliative. Response to treatment 
may be improved by optimizing the timing of radiotherapy in combination with systemic 
therapies. Some studies suggest that radiation can increase vascular permeability within 
tumors and in healthy brain tissue through initiation of endothelial cell apoptosis [10, 11]. 
If WBRT increases permeability of the local BBB in vivo, it may be possible to increase 
drug uptake in brain metastases and improve on the results of systemic therapy or 
radiotherapy alone [12].  
Several contrast agents with varying sizes have been used to assess BBB integrity and 
degree of permeability. Under normal conditions, the intact BBB prevents extravasation 
of contrast agents. Damage to the BBB can therefore be evaluated based on the size, 
charge, and composition of contrast agents that are able to cross the BBB and accumulate 
in the brain. Traditionally BBB permeability has been studied by microscopy using 
agents such as sodium fluorescin (376 Da), Texas Red Dextran (3 or 70 kDa), horseradish 
peroxidase (44 kDa), or albumin-bound Evans blue dye (69 kDa) [8, 10, 13–15]. These 
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techniques are limited by their ex vivo nature, inability to monitor changes over time, and 
contrast agent sizes that are not directly relevant to drug uptake. In this work, we evaluate 
BBB integrity in vivo over time using Gd-enhanced MRI, which is routinely used in 
clinical diagnosis to identify BBB breakdown.  
Gd-enhanced MRI has also been used in preclinical cancer models to evaluate BBB 
permeability associated with brain tumors [14, 16–19]. Regions where the BBB has been 
compromised can be visualized due to local accumulation of the Gd contrast agent, which 
results in signal enhancement (brightness) in the image. Using this method, substantial 
heterogeneity has been reported in the permeability of brain metastases. In addition, both 
Gd-permeable as well as Gd-impermeable tumors have been observed within the same 
brain [17, 19]. Notably, Percy and colleagues also found that many metastases were 
impermeable to Gd early in development, but became permeable over time [17]. Here, we 
build on these results by investigating whether radiation therapy increases the 
permeability of brain metastases, to understand if it is possible to open a window where 
systemic therapy could have increased efficacy.   
In this study, we developed a clinically relevant WBRT treatment protocol that is feasible 
in the MDA-MB-231-BR-HER2 experimental brain metastatic breast cancer model. We 
used this model along with contrast enhanced MRI and high resolution anatomical MRI 
to investigate the impact of clinically relevant radiation treatment on the growth of brain 
metastases due to breast cancer and on BBB integrity in a murine model. We 
hypothesized that radiotherapy will decrease the tumor burden in treated animals and 
increase tumor permeability.  
3.2 Methods 
3.2.1 Cell Culture 
The brain metastatic breast cancer cells (MDA-MB-231-BR-HER2) used in this research 
were a kind gift from Dr. Patricia Steeg’s laboratory at the National Cancer Institute 
(Bethesda, MA) [20, 21]. Cells were grown in Dulbecco’s Modified Eagle Medium with 
10% fetal bovine serum, 1% penicillin and streptomycin, and were maintained at 37°C 
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and 5% CO2. Culture media and supplements were purchased from Thermo Fisher 
Scientific (Mississauga, ON). The cell line was tested for mycoplasma contamination 
using the MycoAlert Mycoplasma Detection Kit (Lonza, Rockland, ME, USA) and was 
found to be negative. The trypan blue exclusion assay was used to determine cell 
viability. 
3.2.2 Animal Preparation 
Female nude mice (nu/nu, aged 6-8 weeks from Charles River Laboratories, Wilmington, 
MA, USA) were housed in a pathogen-free barrier facility at Robarts Research Institute. 
All experiments were approved by the Animal Use Subcommittee of the University 
Council on Animal Care at the University of Western Ontario. Mice (n=2 for 
commissioning, n=12 for WBRT experiment) were anesthetized with 2% isoflurane in 
oxygen, and given an intracardiac injection of 100,000 MDA-MB-231-BR-HER2 cells 
suspended in 0.1mL of HBSS. Mice were euthanized by an overdose injection of 
pentobarbital (Euthanyl) after the final imaging session.  
3.2.3 Radiotherapy 
We previously developed an integrated micro-CT/RT system capable of sophisticated 
image-guided conformal small animal radiotherapy [22]. The micro-irradiation 
technology is based on a modified preclinical micro-CT system (GE eXplore CT 120, GE 
Healthcare, Milwaukee, WI, USA) with an upgraded x-ray generator (140 kVp, 50 kW), 
custom irradiation control software (Parallax-Innovations, London, ON, Canada), and a 
custom-built computer-controlled collimator. Thus far, it had been used for respiratory-
gated rat lung irradiation and was commissioned for mouse WBRT in this work [22, 23]. 
Mice were anesthetized (1.5% isoflurane in oxygen), placed feet first prone on the rodent 
couch, and aligned using set up lasers and CT imaging. On-board fluoroscopy was used 
to identify the skull and position computerized collimators such that the whole brain was 
targeted for irradiation and the remainder of the head and body were shielded. Animal 
temperature was maintained using a heating pad and breathing rate was monitored during 
treatment. 
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3.2.4 Magnetic Resonance Imaging 
Magnetic resonance images were acquired on a 3.0 T GE MR750 clinical scanner 
(General Electric, Mississauga, ON, Canada), using a custom-built gradient insert coil 
(inner diameter = 17.5cm, gradient strength = 500 mT/m, and peak slew rate = 3000 
T/m/s). Mice were anesthetized (1.5% isoflurane in oxygen) and placed in a custom 
solenoidal mouse head radiofrequency (RF) coil (inner diameter = 1.5cm). Animal 
temperature was maintained using warm saline bags during imaging. Anatomical bSSFP 
scans were acquired with the following parameters: spatial resolution = 100 x 100 x 200 
µm, repetition time = 8 ms, echo time = 4 ms, flip angle = 35°, signal averages = 2, 
radiofrequency phase cycles = 8, scan time = 29 minutes. ZIP2 and ZIP512 upscaling 
were applied. Post-Gd T1-weighted spin echo (T1w SE) images were acquired at 
approximately 45 minutes after an ip injection of 0.2mL gadopentetate dimeglumine 
(Magnevist, 0.5 mmol/mL). The parameters were: spatial resolution = 156 x 156 x 400 
µm, repetition time = 600 ms, echo time = 20 ms, signal averages = 8, scan time = 20 
minutes. ZIP512 upscaling was applied.  
3.2.5 Data Analysis 
Open-source OsiriX image software (version 3.9.2) was used for image analysis. Brain 
metastases were counted and the boundaries of each were manually segmented using the 
ROI tool in every bSSFP slice throughout the whole mouse brain. Tumor volume was 
then calculated by a 3D reconstruction using the Osirix volume algorithm. Enhancing 
fraction (reflecting Gd-permeable tumors) was determined as previously described by 
comparing tumor detection in corresponding post-Gd T1w SE and bSSFP images [17, 
19]. Metastases that are detected in both the post-Gd T1w SE and the bSSFP sequences 
are considered ‘enhancing’; tumors appearing in only the bSSFP images are ‘non-
enhancing’. Tumors detected in bSSFP without a corresponding T1w SE image slice 
were excluded from the enhancement analysis.  
Statistical analysis was performed using GraphPad Prism version 6.0 software 
(GraphPad, San Diego, CA, USA). Where two groups were compared, two-way paired or 
unpaired Students t-tests were performed. Where two groups were compared over 
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multiple time points, two-way repeated measures analysis of variance (ANOVA) were 
performed. For enhancement-related statistical analyses over time, one untreated mouse 
was removed due to unsuccessful injection on day 32, therefore repeated measures was 
not used for this analysis. Post hoc analysis included Sidak’s multiple comparisons tests.   
3.2.6 Histology and Immunohistochemistry 
At experimental endpoint, mice were first perfused with 0.9% saline before perfusion 
fixation with 4% formalin; brains were then excised, further fixed for 24 hours by 
immersion in 4% formalin, processed, paraffin-embedded, cut into 5-µm sections, and 
stained with hematoxylin and eosin (H&E) for morphology, or stained by IHC for the 
proliferation marker Ki67, or human mitochondria (clone MTCO2). Briefly, Ki67 
staining was achieved on selected brain sections using heat mediated antigen retrieval 
with citrate buffer pH6. Tissue sections were blocked with Dako protein block, serum 
free (Dako Canada, Inc, Burlington, ON, Canada) and incubated with anti-ki67 (1:100, 
ab833, Abcam Inc) rabbit polyclonal antibodies. Positive staining was detected using 
Dako LSAB2 system-HRP (Dako Canada Inc) and Vector DAB peroxidase substrate kit 
(Vector Laboratories, Burlingame, CA, USA) according to manufacturer’s instructions. 
Mouse anti-human mitochondria antibody (clone MTCO2, 1:100) was used with the 
Dako Animal Research Kit according to manufacturer’s instructions for detection of 
human cells. All sections were counterstained with hematoxylin.   
For commissioning studies, mice were perfused with 0.9% saline before perfusion 
fixation with 4% paraformaldehyde; brains were excised, further fixed for 24 hours by 
immersion in 4% formalin, placed in ascending sucrose gradients (10%, 20%, 30%), 
embedded in optimal cutting temperature compound (Tissue-Tek, Sakura, Torrance, CA, 
USA), frozen, cryosectioned with 10 µm thickness and stained by IHC for γ-H2AX using 
the Ford protocol [24]. Sections were incubated with mouse anti-γ-H2AX antibody 
(1:700, anti-phospho-histone H2AX, Ser139, clone JBW301; Millipore, Billerica, MA, 
USA) overnight and the stained with secondary antibody Alexa-Fluoro 594 goat anti-
mouse IgG (1:500, Life Technologies, Carlsbad, CA, USA) for one hour at room 
temperature. All sections were counterstained with DAPI (4', 6-diamidino-2-
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phenylindole) and mounted with anti-fade medium Vectashield (Vector Laboratories, Inc. 
Burlington, ON, Canada).  
All staining was imaged on an Axio Imager A1 microscope (Zeiss CANADA, Toronto, 
ON, Canada) with a Retiga EXi (QImaging Scientific Research Cameras, Surrey, BC, 
Canada) digital camera. Whole brain histology images were acquired using the 
TISSUEscope 4000 (Huron Digital Pathology, Waterloo, ON, Canada). For γ-H2AX 
confocal images, an inverted confocal microscope (Olympus Fluoview FV1000 Confocal 
Imaging System) was used. 
3.3 Results 
3.3.1 Radiation Therapy Planning and Verification 
First, the integrated micro-CT/RT system used in this research was implemented for 
mouse WBRT.  A treatment plan of 20 Gy in two fractions on consecutive days was 
implemented based on the biological effective dose (BED) to tumor (assuming α/β=10 
Gy) to be equivalent to the clinical WBRT dose fractionation scheme of 30Gy/10. Image 
guidance allowed for precise isolation of the mouse brain in a collimated 10x14-mm 
field; fluoroscopy images show the uncollimated field (Figure 3.1A) and collimated field 
(Figure 3.1B). The brain was irradiated with two identical fields using a parallel-opposed 
beam set-up. One beam was delivered from the animal’s left-right direction and one from 
right-left, for a cumulative dose of 10 Gy per fraction. A Monte Carlo dose verification 
calculation was performed to confirm delivery of the treatment plan (10 Gy is shown by a 
green line) (Figure 3.1C). Mean dose rate was 0.12 ± 0.01 Gy per minute.  
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Figure 3.1: Micro-CT/RT targeting for mouse WBRT.  Fluoroscopy-guided 
collimation of the mouse brain (A, B) allows for precise delivery of the 10Gy per 
fraction treatment plan. Dosimetry was verified using a Monte Carlo dose 
calculation, where the 10-Gy isodose line is delineated in green (C). The brain 
received a uniform dose of 10 Gy. Enhanced dose to the skull is observed due to the 
low energy of the beam (140kV) where photoelectric effect is prominent.  
  
 
90 
Immunohistochemistry was performed after irradiation to confirm adequate whole brain 
coverage by the radiotherapy plan. Irradiation-induced DNA damage response was 
verified by fluorescent γ-H2AX immunohistochemistry and the DAPI nuclear stain; this 
confirmed the actual whole brain radiation field in tissue. Whole brain sections bearing 
MDA-MB-231-BR-HER2 metastases were imaged with a fluorescent microscope at 10x 
magnification; these showed no damage to un-irradiated mouse brain (Figure 3.2A) and 
confirmed homogeneous γ-H2AX response to radiation-induced DNA double stranded 
breaks (DSB, red foci) across the whole treated mouse brain 30 minutes after the second 
fraction of 20Gy/2 (Figure 3.2B). Intrinsic DNA DSB response was evaluated in 100x 
magnification images of tumor tissue and normal brain of an un-irradiated mouse (Figure 
3.2C,D) and compared with initial DNA DSB response in a mouse brain 30 minutes post-
irradiation (Figure 3.2E,F). Increased γ-H2AX intensity is evident in both tumor and 
normal brain tissue in the mouse brain treated with WBRT compared to untreated. 
Confocal microscopy confirms accumulation of γ-H2AX within the nuclei of tumor cells. 
While few intrinsic γ-H2AX foci are present in nuclei of un-irradiated tumor cells (Figure 
3.2G), they are highly prevalent in response to DNA DSB at 30 minutes post-irradiation 
(Figure 3.2H).  
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Figure 3.2: Response to radiation-induced DNA DSB was visualized by fluorescent 
γ-H2AX immunohistochemistry.  This staining was performed 30 minutes post-
radiotherapy with fluorescent γ-H2AX (red foci) on a nuclear DAPI background 
(blue) on whole brain sections of untreated (A) and WBRT-treated (B) mouse brain. 
Magnified images of untreated tumor (C) and normal brain (D) showed minimal γ-
H2AX signal intensity compared to irradiated tumor (E) and irradiated normal 
brain (F). Confocal microscopy illustrated the accumulation of γ-H2AX was within 
the nuclei of tumor cells; untreated nuclei had few intrinsic γ-H2AX foci (G) and 
treated nuclei had many γ-H2AX foci in response to radiation-induced DNA DSB. 
Scale bars are 750 micron (A,B), 50 micron (C-F), and 20 micron (G,H). 
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Brain sections were also assessed at endpoint (day 36 post cell injection) to confirm 
imaging results, evaluate proliferation in tumors, and verify human status of the 
developing cancer (Figure 3.3).  Hyperintense regions in the MRI (Figure 3.3A) 
corresponded to tumor regions as assessed by morphology in standard H&E histology 
(Figure 3.3B, E). Ki67 staining of neighboring sections indicated that the detected tumors 
were proliferative (Figure 3.3C, F). Staining for human mitochondria also confirmed the 
metastases were of human origin (Figure 3.3D, G). The histology and 
immunohistochemistry therefore validate that the MRI findings in this study reflect 
cancerous growth due to the injected MDA-MB-231-BR-HER2 cell line.  
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Figure 3.3: Representative MRI with correlative histology and 
immunohistochemistry of metastases in the MDA-MB-231-BR-HER2 brain 
metastasis model.  Staining for H&E (B, E), Ki67 (C, F), and human mitochondria 
(D, G) at 10x magnification (B-D, white scale bar = 250 µm) and 40x magnification 
(E-G, black scale bar = 100 µm) supports the imaging data and confirmed MRI-
detected lesions were proliferative cancerous tumors of human origin.  
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3.3.2 WBRT Experiment 
Next, the micro-CT/RT system was used to deliver WBRT (20Gy/2) to nude mice with 
brain metastatic breast cancer. Treatment was delivered when mice developed small 
MRI-detectable brain tumors (day 24 and 25 post-cell injection); this timing mimics the 
usual treatment following diagnosis that occurs in the clinic. Three dimensional, high-
resolution anatomical bSSFP MRI was used to detect and monitor tumor progression over 
time. Radiological findings correspond well with tumor burden in whole brain histology 
sections (Figure 3.4).  
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Figure 3.4: Representative images of metastases due to MDA-MB-231-BR-HER2 
human brain metastatic breast cancer on day 36.  bSSFP MRI illustrated metastasis 
burden by the appearance of hyperintensities (A) and this corresponded with tumor 
detection in H&E stained sections (B). 
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The number of tumors, total tumor volume, and mean tumor volume over time (day 23, 
32, 36) were quantified in bSSFP images and these data are presented in Table 3.1. 
WBRT did not have an effect on the number of tumors, nor total tumor volume over time, 
however, it did have an effect on the mean volume of a tumor over time (p<0.01); post 
hoc analysis found mean tumor volume was significantly less in WBRT-treated mice than 
untreated (p<0.001).  
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Table 3.1: Quantification tumor incidence, burden, and mean tumor volume from 
MRI in the traditional WBRT experiment.  The number of tumors and total tumor 
volume in the mouse brain increased over time from day 23 to 36, but there was no 
difference between treatment groups for these measurements. Traditional WBRT 
had a significant effect on mean tumor volume over time; post hoc analysis between 
groups indicated that by day 36, on average, tumors were smaller in treated mice 
compared to untreated. Data are presented as mean ± SD. N=6 for each group. 
Analysis Day 23 Day 32 Day 36 Main effect 
 untreated WBRT untreated WBRT untreated WBRT  
Number of 
Tumors 
7.0 ± 11 25 ± 29 17 ± 19 34 ± 33 
 
18 ± 19 
 
34 ± 33 
 
time 
p < 0.0001 
 
Total 
Tumor 
Volume 
(mm3) 
0.26 ± 0.41 0.98 ± 1.4 4.9 ± 5.8 8.3 ± 9.8 9.8 ± 11 8.4 ± 9.3 
time 
p < 0.01 
Mean 
Tumor 
Volume 
(mm3) 
0.030±0.022 0.035±0.014 0.33±0.18 0.23±0.067 0.67±0.40 0.23±0.059 
interaction 
between time and 
treatment 
p  < 0.01 
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Substantial variability was observed in tumor response after WBRT. The changes in 
volume of 209 treated tumors were analyzed between 7 and 11 days post-treatment (day 
32 and 36). A paired two-tailed t-test found no significant difference between the fraction 
of tumors that decreased in volume after WBRT compared to the fraction that increased 
(Figure 3.5A). Furthermore, despite the same treatment plan, some mice had more tumors 
that decreased in volume after radiotherapy than others.  For example, as shown in Figure 
3.5B, 85% of the brain tumors in mouse B had a decreased volume after WBRT whereas 
only 15% of the tumors in mouse E had a decreased volume after WBRT. 
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Figure 3.5: Treatment response was heterogeneous after traditional WBRT.  There 
was no significant difference between the fraction of tumors that decreased in 
volume after traditional WBRT and the fraction that continued to increase (A). In 
addition, the response to therapy was markedly different for each mouse, ranging 
from 15 - 85% of the tumors in a mouse brain being reduced in tumor volume 
following treatment (B). Error bars are standard deviation. 
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Next, BBB integrity was evaluated by determining the ability for Gd to accumulate 
within tumors and cause increased signal intensity (enhancement). Analysis of BBB 
permeability by enhancement in T1w SE post-Gd images was performed as previously 
described and representative MR image slices of the same mouse brain are shown in 
Figure 3.6A,B [17, 19]. The enhancing fraction over time is shown in Figure 3.6C.  Over 
time, a higher proportion of enhancing metastases are detectable in both groups 
(p<0.0001). Of the non-enhancing tumors present in untreated mice (black bars) on day 
32, 29% (9 of 31) changed to enhancing by day 36. Similarly, 26% (6 of 23) of non-
enhancing tumors in WBRT mice (white bars) changed to enhancing in the same time 
frame. WBRT did not increase the fraction of enhancing tumors.  
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Figure 3.6: Tumor permeability visualized and quantified over time by contrast-
enhanced MRI.  Enhancing fraction (representing Gd-permeable tumors) was 
quantified as the number of enhancing tumors relative to total tumor burden by 
assessment of T1w SE post-Gd (A) and bSSFP images (B). Black arrows indicate 
metastases that were detected in both the T1w SE and the bSSFP sequences; these 
were considered ‘enhancing’. White arrows indicate metastases that were detected 
in the bSSFP image but were absent in the corresponding post-Gd T1w SE image; 
these were considered ‘non-enhancing’.  Over time, the enhancing fraction 
increased in both groups; treatment did not have any significant effect (p > 0.05) 
(C). Error bars represent standard deviation.  
  
 
102 
Temporal analysis of enhancement status and mean tumor volume (Figure 3.7) found 
enhancing tumors grow larger than non-enhancing tumors over time in both untreated and 
WBRT-treated groups (p<0.001, p<0.01 respectively). Post hoc analysis found that 
enhancing tumors are significantly larger than non-enhancing on day 32 and 36 in both 
groups (untreated: !!p<0.05, !p<0.0001. WBRT: °°p<0.0001, °p<0.0001). Radiotherapy 
affected the growth of enhancing and non-enhancing tumors differently (Figure 3.7, 
striped vs. solid bars). Over time, WBRT had an increased effect on the size of enhancing 
tumors (p<0.01); post hoc analysis between treatment groups showed that the mean 
volume of enhancing tumors is significantly less in WBRT treated mice compared to 
untreated on day 36 (*p<0.0001). Contrarily, time and treatment group did not affect the 
volume of non-enhancing tumors.  
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Figure 3.7: Enhancing and non-enhancing tumors respond differently to WBRT.  In 
both untreated and WBRT-treated mice, enhancing tumors were larger than non-
enhancing tumors at day 32 and at day 36 (statistical significance indicated by !! , ! , 
°°, °). By day 36, the mean volume of an enhancing tumor in a treated mouse was 
significantly less than untreated (*); however, there was no difference between 
groups in the volume of non-enhancing tumors. Error bars represent standard 
deviation.  
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3.4 Discussion 
This research used high-resolution anatomical and contrast-enhanced MRI in a murine 
model of breast cancer brain metastasis to monitor tumor development and permeability 
in vivo. This was combined with novel image-guided micro-irradiation technology to 
provide insight into the responses of tumors and alternations in BBB integrity in a 
clinically relevant model of breast cancer brain metastasis and WBRT.  
A micro-CT/RT system with asymmetrical computerized jaws was successfully applied 
to deliver mouse whole brain irradiation. These are the first experiments where such a 
system has been used to demonstrate the effects of WBRT on brain metastatic 
development. This technology has the capacity to target and deliver conformal irradiation 
to the mouse brain via onboard image-guided collimation. Post-irradiation, γ-H2AX 
staining confirmed response to radiation-induced DNA DSB was present and was 
uniform across the whole mouse brain. Dose rate was low compared to other preclinical 
irradiators; however, doses up to 20 Gy per fraction can be delivered in one session, and 
increased dose can compensate for the lower dose rate [25, 26]. Here, we chose 20 Gy/2 
to keep side effects at a minimum while delivering biological effective doses that are 
relevant for WBRT.  
Using this small animal irradiation system, traditional WBRT was given after MRI 
detected tumors; this sequence, where treatment follows diagnosis, is the usual order of 
events in the clinic. WBRT was able to mitigate tumor growth, though it could not 
eliminate the tumor burden. Similar results were reported by Smart and colleagues who 
observed that fractionated (3 Gy x 10 fractions, starting on day 14 post-injection) or 
single dose (15 Gy x 1 fraction on day 14) radiotherapy could reduce, but not eliminate, 
the number of large and micrometastases in the 231-BR experimental brain metastasis 
model [27]. In our study, the largest contributor to the drop in mean tumor volume of 
treated animals was a decrease in the mean volume of enhancing tumors.  On the 
contrary, non-enhancing tumor volumes, though significantly less by comparison, were 
not different between treatment groups. Increased BBB permeability with tumor size, in 
addition to innate BBB heterogeneity, has been reported by several groups and 
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investigated for its impact on systemic drug delivery [8, 17, 18, 28, 29]. However, to the 
best of our knowledge, this is the first report indicating that impermeable tumors may not 
respond to radiotherapy in the same way as their permeable counterparts.  
Increased vascular permeability and BBB disruption after irradiation have been well 
documented [10, 11, 30]. This stimulated the idea that radiotherapy may be a useful 
mechanism to improve chemotherapeutic efficacy by increasing drug uptake though 
breakdown of the BBB, which is usually prohibitively exclusive to anti-cancer drugs. 
Yet, clinical studies investigating combinations of chemo- and radiotherapy remain 
inconclusive [31–33]. Previous studies may have offered poor insight due to limitations 
by their in vitro or ex vivo nature, non-translational animal models, and irradiation doses 
that are not clinically relevant [10, 11]. Moreover, no study has looked at these effects in 
the context of brain metastasis. Our study addresses all of these limitations; we used MRI 
tumor enhancement post-Gd administration to assess tumor permeability in vivo and 
found that the fraction of enhancing tumors was not different between treated and 
untreated mice at any time point.  Furthermore, the percent of tumors that change from 
non-enhancing to enhancing was similar after WBRT compared to untreated. Notably, 
tumor enhancement post-Gd administration reflects sufficient BBB permeability to allow 
the 590 Da Gd-based contrast agent to cross; this is approximately the same molecular 
weight as lapatinib (581 Da), a dual tyrosine kinase inhibitor used in combination therapy 
for HER2+ metastatic breast cancer patients. Taskar and colleagues previously reported 
limited BBB permeability in the vast majority of brain metastases contributed to poor 
therapeutic efficacy for this drug [28]. Our study, using Gd as a permeability marker, did 
not find a suitable mechanism to increase tumor permeability. Our results suggest that 
increased BBB permeability due to clinically relevant radiotherapy, as measured by 
enhancement post-Gd administration, is not present at one week, or 11 days post-WBRT 
as was previously hypothesized [12]. Moreover, the idea that radiotherapy can increase 
BBB permeability and thereby improve drug delivery is not feasible in this model.  
In summary, this research developed technology for image-guided mouse WBRT and 
used it with high resolution anatomical and contrast-enhanced MRI to investigate tumor 
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and BBB response after radiotherapy in a mouse model of breast cancer brain metastasis. 
Contrary to previous hypotheses, increased tumor permeability after radiotherapy was not 
found, although enhancing tumors decreased in volume after radiotherapy and non-
enhancing tumors did not. 
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Chapter 4  
4 MRI surveillance of cancer cell fate in a brain 
metastasis model after early radiotherapy 
Purpose: Incidence of brain metastasis due to breast cancer is increasing and prognosis is 
poor. It is thought that disseminated dormant cancer cells persist in metastatic organs and 
may evade treatments, thereby facilitating a mechanism for recurrence. Radiotherapy is 
used to treat brain metastases clinically, but assessment has been limited to macroscopic 
tumor volumes detectable by clinical imaging. Here, we use cellular MRI to understand 
the concurrent responses of metastases and non-proliferative or slowly-cycling cancer 
cells to radiotherapy. Methods: MRI cell tracking was used to investigate the impact of 
early cranial irradiation on the fate of individual iron-labeled cancer cells and outgrowth 
of breast cancer brain metastases in the human MDA-MB-231-BR-HER2 cell model. 
Results: Early whole brain radiotherapy significantly reduced the outgrowth of 
metastases from individual disseminated cancer cells in treated animals compared to 
controls. However, the numbers of non-proliferative iron-retaining cancer cells in the 
brain were not significantly different. Conclusions: Radiotherapy, when given early in 
cancer progression, is effective in preventing the outgrowth of solitary cancer cells to 
brain metastases.  Future studies of the non-proliferative cancer cells’ clonogenic 
potentials are warranted, as their persistence presence suggests that they may have 
evaded treatment. 
4.1 Introduction 
When a metastatic breast cancer cell arrives in a distant organ – commonly bone, liver, 
lung, or brain – it may (1) die, (2) proliferate to form a metastatic tumor, or (3) remain 
viable, but dormant [1,2]. The complex relationship between these fates and their 
interplay when responding to treatment is poorly understood. Apparently successful 
cancer treatment often does not fully eradicate the disease and recurrences can manifest 
several years, or even decades, after the patient was believed to be disease-free [3]. Late 
recurrence (years or decades) implies the presence of dormant cancer cells that hide 
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within the patient until some yet unknown trigger causes them to proliferate and form 
clinically relevant metastases.  
Prophylactic cranial radiation (PCI) decreases the incidence of brain metastases in SCLC 
patients [4,5]. Brain metastasis is an emerging therapeutic challenge in HER2+ breast 
cancer as advances in systemic therapy have resulted in improved extra-cranial disease 
control. Here, we investigate the potential use of PCI for these patients, where likelihood 
of developing brain metastasis approaches 50%, even when women are responding to 
systemic treatment [6,7]. Since PCI has a number of dose-dependent risks and side 
effects, improved understanding of brain metastatic breast cancer and especially solitary 
cancer cell responses to PCI is needed to determine the potential efficacy of this 
treatment in breast cancer patients [4,8].   
Cellular MRI provides a powerful tool for cancer cell tracking and investigating 
treatment responses. This technique facilitates detection of iron-labeled cancer cells after 
initial arrest in an organ and surveillance as they develop into metastatic tumors [9]. 
Furthermore, non-proliferative cancer cells can be tracked by virtue of their long-term 
retention of iron particles [9–11].  
This study employed cellular MRI to evaluate the concurrent responses of cancer cells 
and resulting metastases to early radiation treatment in a brain metastatic model of breast 
cancer. We hypothesized that early radiotherapy would prevent the outgrowth of 
disseminated cancer cells thereby mitigating tumor burden but the number of non-
proliferative cancer cells would not be affected. Herein we demonstrate that cell tracking 
techniques are critical for a complete understanding of treatment response.  
4.2 Methods 
4.2.1 Cell Culture 
Human brain metastatic breast cancer cells (MDA-MB-231-BR-HER2), previously 
transduced with enhanced green fluorescent protein (eGFP), were a kind gift from Dr. 
Patricia Steeg’s laboratory at the National Cancer Institute (Bethesda, MA, USA) [12]. 
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Cells were grown in DMEM containing 10% FBS, 1% penicillin and streptomycin, and 
0.375 mg/mL zeocin. Culture media and supplements were purchased from Thermo 
Fisher Scientific (Mississauga, ON). For tracking, cells were labeled with iron oxide 
nanoparticles (0.9 µm MPIO, 62% magnetite, labeled with Flash Red; Bangs Laboratory, 
Fishers, IN, USA) as previously described [9]. Cell viability was measured by trypan blue 
exclusion and was not significantly different from previous experiments using unlabeled 
cells. Perl’s Prussian Blue (PPB) stained cells were analyzed to evaluate iron labeling 
efficiency. The cell line was tested for mycoplasma contamination using the MycoAlert 
Mycoplasma Detection Kit (Lonza, Rockland, ME, USA) and was found to be negative.  
4.2.2 Animal Preparation 
Female nude mice (nu/nu, aged 6-8 weeks from Charles River Laboratories, Wilmington, 
MA, USA) were housed in a barrier facility. Experiments were approved by the Animal 
Use Subcommittee of the University Council on Animal Care at the University of 
Western Ontario. Mice (n=17) were anesthetized with isoflurane and given an 
intracardiac injection of 175,000 iron-labeled cells suspended in 0.1mL of HBSS (day 0). 
Mice were euthanized by pentobarbital (Euthanyl) overdose after the final imaging 
session. Group 1 (n=2, one with cells injected and one without) was euthanized on day 0 
for tissue analysis. Group 2 (n=6) was untreated and euthanized on day 32, which is the 
typical endpoint for this model due to deteriorating health. Group 3 (n=6) was treated 
with WBRT, as described below, and also euthanized on day 32. Interestingly, Group 3 
mice still appeared healthy at the pre-determined endpoint; therefore, an additional group 
(Group 4, n=4) was added to this study. Group 4 received identical treatment to Group 3, 
but was not sacrificed until health complications were observed.  
4.2.3 Radiotherapy 
A radiation treatment plan of 20 Gy total dose in two 10 Gy fractions to the whole mouse 
brain was delivered on days 1 and 2 post cell injection using a custom micro-irradiation 
system with on-board image guidance previously developed by our group [13]. This dose 
fractionation schedule was chosen because it is the equivalent biological effective dose 
(BED) to tumor (assuming α/β=10 Gy) of a typical 30Gy/10 clinical WBRT plan and is 
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feasible in the animal model with the micro-CT/RT system. Mice were anesthetized with 
isoflurane and aligned using set up lasers in the feet first prone position on the rodent 
couch for CT imaging. The skull was identified using on-board fluoroscopy and custom-
built computerized collimators were positioned such that a 10x14 mm (Groups 1-3) or 
20x14 mm (Group 4) field encompassed the brain and shielded the remainder of the 
mouse head and body. The whole brain was irradiated with two equal-weighted parallel-
opposed beams for a cumulative dose of 10 Gy per fraction. Mean dose rate was 0.13 ± 
0.01 Gy per minute. One mouse in Group 4 was only treated to 10 Gy in one fraction due 
to equipment problem on day 2.  
4.2.4 Magnetic Resonance Imaging 
MRI was performed using a 3.0 T GE MR750 clinical scanner (General Electric, 
Mississauga, ON, Canada), with a custom insertable gradient coil and a custom mouse 
head radiofrequency coil [14]. Isoflurane anesthesia was used during scans and 
temperature was maintained with warm saline bags. Images were acquired using bSSFP 
with the following parameters: spatial resolution = 100x100x200 µm, repetition time = 18 
ms, echo time = 9 ms, flip angle = 35°, signal averages = 1, radiofrequency phase cycles 
= 8, scan time = 32 minutes. A subset of scans on day 32 and later used the following 
parameters for to optimize contrast for co-detection of voids and tumors: repetition time 
= 10 ms, echo time = 5 ms, averages = 2, scan time = 35 minutes. ZIP2 and ZIP512 
upscaling were applied.  
4.2.5 Data Analysis 
Image analysis was performed using open-source OsiriX image software (version 3.9.2). 
Brain metastases were manually counted and segmented in each of the 176 image slices 
per mouse. The region-of-interest volume tool was used to calculate tumor volume. 
Signal voids were manually counted in 22 image slices distributed regularly over the 
image set. The fractional signal loss (FSL) was measured in a subset of voids persisting 
between day 0 and 32 in one treated and one untreated animal. FSL describes the amount 
of contrast in a region of signal void by signal intensity (SI) measurements (Equation 1) 
and can be related to the amount of iron per voxel [15].  
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FSL = ! !"!"#$%!!!"!"#$!"!"#$%                                               (Equation 1) 
Statistical analysis was performed using GraphPad Prism version 6.0 software 
(GraphPad, San Diego, CA, USA). Two-way unpaired Student’s t-tests were used to 
compare two groups at a single time point. Two-way repeated measures analysis of 
variance (ANOVA) with post hoc Sidak’s multiple comparisons tests were used to 
compare two groups over multiple time points.   
4.2.6 Histology and Immunohistochemistry 
At endpoint, mice underwent perfusion fixation and brains were either paraffin-
embedded or frozen. Brain sections were stained with hematoxylin and eosin (H&E) for 
morphology or PPB for iron. The presence of micro-metastases (not detected with MRI) 
was evaluated in 18-28 sections per irradiated mouse brain. Brain sections were imaged 
on an Axio Imager A1 microscope (Zeiss CANADA, Toronto, ON, Canada) with a 
Retiga EXi (QImaging Scientific Research Cameras, Surrey, BC, Canada) digital camera. 
GFP and Texas Red filters were applied as necessary for fluorescence microscopy. 
Whole brain histology images were acquired using the TISSUEscope 4000 (Huron 
Digital Pathology, Waterloo, ON, Canada). 
4.3 Results 
The mouse brain was imaged using bSSFP to co-detect both iron-retaining cancer cells 
(signal voids) and tumors (hyperintensities) over time. Figure 4.1A illustrates a 
representative in vivo image slice through the brain of a control mouse that did not 
receive cancer cells or treatment. Cancer cells readily took up MPIO and a labeling 
efficiency of nearly 100% was achieved without affecting viability (Figure 4.1B). After 
intracardiac injection (day 0) and initial arrest in the brain, approximately 1% of iron-
labeled cancer cells were detected as regions of signal void (Figure 4.1C); this delivery is 
in agreement with other studies [9,16]. Regions of discrete signal void in MRI were 
correlated optically to areas of both GFP and Flash Red fluorescence for the first time, 
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indicating the presence of live, MPIO-labeled MDA-MB-231-BR-HER2 cells (Figure 
4.1D-G).   
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Figure 4.1: Visualization of iron-labeled cancer cell delivery with cellular MRI.  
bSSFP MRI illustrates the appearance of normal mouse brain prior to cell injection 
(A). In vitro, intracellular iron (blue, PPB) was detected within MDA-MB-231-BR-
HER2 cells (pink, Nuclear Fast Red) labeled with MPIO (B). Successful delivery of 
iron-labeled cells to the brain was visualized as discrete regions of signal void in day 
0 bSSFP MRI (C). Two signal voids detected on MRI (indicated by white arrows in 
C) were optically matched to regions that were both green and red fluorescent (D, 
co-localization appears yellow in the merged image). The green fluorescence results 
from the GFP+ cancer cells and the red fluorescence comes from the MPIO. The 
region indicated by the white arrow in D was viewed under 100x magnification (E-
G) and validates that signal voids in MRI represent live, iron-labeled cancer cells. 
Data is from Group 1 mice euthanized on day 0. Scale bars are 100 µm (B, D) and 
20 µm (E-G).  
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As cancer cells divide the iron label was diluted, thus rendering proliferative cancer cells 
undetectable over time. By day 32, tumors were detectable in bSSFP images as 
hyperintense regions due to the dominating effect of pathology-induced changes to local 
relaxation rates (Figure 4.2, white arrow). A subset of non-proliferative cancer cells 
retained the iron label and remained detectable long-term alongside metastases (Figure 
4.2 top row, white arrowheads). Of particular interest is the observation that cancer cells, 
when treated with radiotherapy soon after arrest in the brain, rarely developed into tumors 
(Figure 4.2, bottom row). Of the few tumors that did form in WBRT-treated mice, all 
were found at the edge of the irradiation treatment field in the hindbrain. Furthermore, 
residual signal voids were consistently observed in the brain after early WBRT, despite 
prevention of the tumor burden (Figure 4.2 bottom row, white arrowheads). 
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Figure 4.2: Monitoring cancer cell fate over time by dilution or retention of the iron 
oxide label.  Balanced steady state free precession MR imaging can co-detect signal 
voids and developing tumors within the same mouse brain. The white arrow 
indicates a proliferative cancer cell. On day 0 it is present as a signal void; however 
the iron label is diluted as it proliferates and cannot be detected by day 4. On day 32 
a tumor is visible in its place. Several other tumors are also visible in the brain and 
each arose from signal voids that were present in the same location on day 0 (note: 
the above figure displays single image slices only from a 3D image set and some 
visible tumors resulted from signal voids that were seen in neighboring slices on day 
0).  The white arrowheads indicate non-proliferative cells that retain their iron and 
remain as signal voids over time.  
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Representative image slices of mouse brain at endpoint (day 32) with corresponding 
whole brain H&E are shown in Figure 4.3. Metastases developed throughout the entire 
brain of untreated mice as seen in MRI and verified by histology (Figure 4.3, top rows). 
In comparison, MRI of treated mouse brain was largely free of macroscopic lesions. 
H&E stained brain sections from WBRT-treated mice were analyzed to determine if 
micro-metastases were present below the threshold for MRI detection and none were 
found (Figure 4.3, bottom rows). This suggests early WBRT was able to nearly eradicate 
all metastatic lesions throughout the whole mouse brain.  
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Figure 4.3: Representative images of forebrain, midbrain, and hindbrain at 
endpoint.  bSSFP images with correlative histology are shown of an untreated 
mouse (top) and a mouse treated with early WBRT (bottom) at day 32 post cell 
injection. Metastases developed throughout the whole brain in untreated mice and 
are circled in black. Metastases were not detected in either MRI or histology for 
mice treated with early WBRT. 
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The number of metastases, total tumor volume and percentage of voids remaining were 
quantified in the whole mouse brain (Figure 4.4).  On day 32, the number of metastases 
and the total MRI-detectable tumor volume in treated mice were significantly less than 
untreated (p<0.01, p<0.05) (Figure 4.4A,B). The percentage of signal voids, relative to 
day 0, remaining in the brain decreased over time in both groups, as expected (p<0.001). 
However, there was no difference in the number of signal voids in WBRT treated versus 
untreated mice at either day 4 or day 32 (p=ns) (Figure 4.4C).  
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Figure 4.4: Early WBRT was able to prevent the growth of tumors.  Both the 
number of tumors (A) and total tumor volume (B) were significantly less in treated 
mice compared to untreated mice by day 32. The number of signal voids in the brain 
decreased over time, but were not affected by treatment (C). Error bars represent 
standard deviation. 
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The FSL of signal voids is a surrogate measure for the amount of iron within cancer cells 
and was employed as an in vivo MRI indicator of the proliferative status of iron-labeled 
cancer cells within the void over time (Figure 4.5A,B). PPB staining for iron confirmed 
regions of signal void in MR images at endpoint corresponded to iron-positive cells 
(Figure 4.5C, image taken at 40x magnification). FSL did not change over time between 
day 0 and 32 (p=ns) and WBRT also had no effect on FSL (p=ns) (Figure 4.5D). A 
constant FSL suggests that iron content did not decrease within the cancer cells, as it 
would have if the cells were dividing; this indicates that the tracked voids represent non-
proliferative cancer cells.  
  
  
 
126 
 
Figure 4.5: Signal void analysis suggests non-proliferative cancer cells persist after 
early WBRT.  Representative MR images illustrate a region of signal void that 
persists from day 0 (A) to day 32 (B). PPB staining for iron presence indicated iron-
containing cells in the mouse brain (blue) that corresponded to discrete regions of 
signal void (C). FSL of the signal void over time was measured using Equation 1 as 
an imaging marker for iron content within cancer cells. FSL did not change over 
time, or with treatment (D). This indicates that the iron content in the signal voids 
was not changing over time and supports our view that these voids represent non-
proliferative cells that were able to persist in the brain after WBRT. Error bars 
represent standard deviation. Scale bar is 100 µm. 
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An additional cohort treated with early WBRT was kept past the normal one-month 
endpoint for the MDA-MB-231-BR-HER2 model to determine the long-term fate of the 
observed non-proliferative cells. This proved challenging because the hematogenous 
delivery of cancer cells in this model led to extra-cranial relapse at later time points. Still, 
signal voids that were observed on day 32 remained as signal voids over time. 
Interestingly, one mouse that received half of the prescribed dose (first 10 Gy fraction 
only due to equipment failure on day 2) lived to day 100 without developing tumors in 
the brain (Figure 4.6).  
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Figure 4.6: Long-term surveillance of outcome after early radiotherapy.  Low dose 
(10 Gy in 1 fraction) whole brain irradiation was sufficient to prevent metastatic 
growth for over 100 days in the MDA-MB-231-BR-HER2 model. Black arrows 
indicate discrete signal voids that persisted from day 0 to day 95, indicating that 
non-proliferative cancer cells are still present. 
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4.4 Discussion 
Overall, early WBRT was effective and prevented almost all tumor growth in the brain. 
Similarly, other groups have also found that metastatic tumor prevention is achievable 
with early treatment in SCLC or treatment with lapatinib in a brain metastasis model 
[4,5,17]. Considering these results, our preclinical study corroborates the suggestion that 
PCI may be a feasible metastasis prevention mechanism in patients with HER2+ breast 
cancer where the risk of brain metastasis is high [6,7]. Furthermore, the observation that a 
single 10 Gy dose prevented brain metastatic growth and extended survival three-fold 
suggests that lower than conventional WBRT irradiation doses may be effective for 
preventative treatment if delivered early enough in metastatic development when the 
disease is more sensitive to radiation.  
Cellular MRI also illustrated the persistence of discrete signal voids due to iron-retaining 
cancer cells, alongside metastases, in the brain over time. This observation has previously 
been described in other metastasis models and is thought to represent a subpopulation of 
dormant cancer cells [9–11]. Importantly, no difference was observed in the number of 
voids between treatment groups at any time point. This demonstrates, for the first time, 
that irradiation does not alter the size of the non-proliferative cancer cell population.  
These results suggest that non-proliferative cancer cells may be able to persist in the 
brain, even when radiotherapy is delivered early in metastatic progression and prevents 
initial tumor growth. This is in line with other preclinical studies that suggest quiescent 
cells are not responsive to cancer chemotherapies as they are designed to target 
proliferating cells [11]. While the mechanism of DNA damage delivery is different 
between radiotherapy and chemotherapy, the sub-population of non-proliferative cancer 
cells described here, if viable and if clonogenic, present a substantial therapeutic 
challenge. It is thought that some poorly understood trigger could prompt these cells to 
escape from dormancy and grow into clinically relevant metastases some time later. In 
women who have had breast cancer, recurrences can manifest years or even decades after 
the women are thought to be cured of cancer [3]. Further research is warranted to 
understand the disseminated dormant cell population and determine if these cells are able 
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to awaken and re-colonize the brain or other organs. To date, ‘re-awakening’ of 
individual dormant cancer cells has not been directly observed in vivo; however, the MRI 
cell tracking technology described here offers a possible strategy to look for this 
phenomenon. 
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Chapter 5  
5 Summary and Future Work 
This is the first characterization of tumor permeability using contrast-enhanced MRI in 
the SUM-190-BR3, JIMT-1-BR3, and MDA-MB-231-BR-HER2 models; further, it is the 
first investigation of the impact of radiotherapy on brain metastasis permeability in vivo. 
This is also the first study to prevent brain metastasis growth by giving early WBRT and 
the first to track cancer cells in vivo after radiation treatment.   
5.1 Discussion and Conclusions 
The brain is emerging as a sanctuary site for the growth of breast cancer metastasis. This 
thesis employed experimental imaging techniques to monitor brain metastatic tumor 
growth, BBB integrity, and cancer cell dormancy. In addition, a clinically relevant mouse 
whole brain radiation treatment plan was developed using novel micro-irradiation 
technology and used to investigate the impact of radiation treatment on metastases and 
disseminated cancer cells in the brain.  
5.1.1 Chapter 2 – HER2+ Breast Cancer Brain Metastasis Models 
In Chapter 2, three models of HER2+ breast cancer brain metastasis were characterized 
by high resolution anatomical and contrast-enhanced MRI with correlative histology and 
immunohistochemistry. We were the first to describe differences in tumor appearance, 
number, volume, and permeability across the models, despite each model representing 
HER2+ breast cancer. The main findings were: 
1.  Brain metastases in the SUM-190-BR3, JIMT-1-BR3, and MDA-MB-231-
BR-HER2 models had different tumor morphology reflected by different 
MRI contrast in bSSFP images. 
2.  The duration of each model and the mean tumor volume at endpoint was 
significantly different in each model. The endpoints were day 28, 36, and 
64 for the JIMT-1-BR3, MDA-MB-231-BR-HER2, and SUM-190-BR3 
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models respectively. Brain metastases in the MDA-MB-231-BR-HER2 
model were significantly larger than tumors in the other two models.  
3.  The average fraction of Gd-permeable tumors was significantly different 
between models. All SUM-190-BR3 and most JIMT-1-BR-3 tumors took 
up contrast agent, whereas only 63.6% of tumors in the MDA-MB-231-
BR-HER2 model displayed Gd-permeability. 
These findings reflect substantial heterogeneity present in the disease and suggest several 
preclinical models may be required to adequately recapitulate human cancer development 
as well as to address possible differences in treatment response. Our goal for the 
following experiments was to investigate differences in BBB permeability after 
radiotherapy; therefore, based on these studies, we chose to use the MDA-MB-231-BR-
HER2 model due to the higher proportion of impermeable tumors. Overall, understanding 
the heterogeneity present in the models, especially as it relates to tumor permeability, is 
important for improvements in brain metastasis detection and in general for systemic 
treatment delivery.  
5.1.2 Chapter 3 – Brain Metastasis Response to Radiotherapy 
In Chapter 3, we successfully implemented micro-irradiation technology that can deliver 
WBRT to mice and used this system to deliver radiation treatment in the MDA-MB-231-
BR-HER2 murine model. We were the first to report that radiotherapy delivered after 
MRI-detectable tumors had developed in the brain could mitigate, but not eliminate, 
tumor growth and that radiation did not affect BBB permeability associated with tumors. 
The main findings were: 
1.  Fluoroscopy-guided collimation of the mouse brain allowed for precise 
delivery of 10 Gy per fraction WBRT. The treatment plan was designed 
using a Monte Carlo dose calculation and adequate whole brain coverage 
was confirmed by immunohistochemistry.  
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2.  By 11 days post-WBRT, tumor volume was significantly less in treated 
mice compared to untreated mice; however, though smaller in volume, 
many metastases still remained in treated mice. 
3.  Over time, the fraction of Gd-permeable metastases increased in both 
groups. Radiotherapy did not change the fraction of metastases that were 
Gd-permeable at the time points studied (7 or 11 days post-treatment).  
These findings indicate that WBRT of 20 Gy in 2 fractions was not curative in the MDA-
MB-231-BR-HER2 model and suggest treatment should be delivered earlier in tumor 
progression for improved response. Moreover, this dose of radiotherapy was not 
sufficient to increase BBB permeability associated with tumors such that it could be used 
as a method to increase systemic drug uptake in brain metastasis. 
5.1.3 Chapter 4 – Cell Tracking and Impact of Early Radiotherapy 
In Chapter 4, we aimed to improve tumor control by delivering radiation treatment earlier 
in the MDA-MB-231-BR-HER2 model. We tested whether early radiotherapy could halt 
the transition to growth from disseminated solitary cancer cells and reduce tumor burden 
compared to treatment delivered after MRI-detectable metastasis; moreover, we 
investigated if early radiotherapy could alter the number of non-proliferative cancer cells 
that persist in the brain. We were the first to report that early WBRT significantly 
reduced metastatic tumor burden, though persisting non-proliferative cancer cells were 
observed. The main findings of this study were: 
1.  The number of brain metastases and the total MRI-detectable tumor 
volume was significantly less in treated mice compared to untreated. No 
additional micro-metastases were seen in histology of treated mice. 
2.  The percentage of signal voids relative to day 0 decreased over time in 
both groups and was not different between treated and untreated mice at 
any time point studied (day 0, 4, 32).  
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3.  The FSL of voids persisting from day 0 to 32 was not significantly 
different between time points or between treatment groups.  
These findings suggest early WBRT could be an effective preventative treatment by 
inhibiting the outgrowth of solitary cancer cells to brain metastasis in the MDA-MB-231-
BR-HER2 model. Notably, cellular MRI revealed the persistence of non-proliferative 
iron-retaining cancer cells in the brain, which may represent a mechanism for recurrence 
if they are found to be viable and clonogenic.  
5.2 Limitations 
The experimental results presented in this thesis are based on observation in animal 
models that are intrinsically limited. First, the nude mouse (nu/nu) used in the brain 
metastasis models is immune-compromised; it lacks a thymus and is T-cell deficient [1]. 
The potential effects of host immunity on tumor growth, tumor permeability, cancer cell 
dormancy, and response to radiation were not fully accounted for due to the limited 
immune response in this animal. Regardless, the nude mouse is the strain of choice for 
these studies because it cannot reject the human cancer cell lines, yet it is resilient enough 
to withstand repeated removal from the barrier facility and exposure to the MRI and 
micro-CT suites. Secondly, the duration of the animal models is relatively short due to 
the many metastatic tumors that develop in the brain and CNS. This forces 
hypofractionation of radiotherapy treatment plans and limits the potential for dormant 
cancer cells to re-awaken. The timeline may be extended by injecting fewer cells, 
different cell lines with slower growth in vivo, or by employing intra-arterial injections to 
reduce extra-cranial tumor growth [2, 3]. Accordingly, the conclusions in this thesis 
should be interpreted within the context of preclinical models of HER2+ breast cancer 
metastasis to the brain; specifically, Chapter 2 investigates the SUM-190-BR3, JIMT-1-
BR3, and MDA-MB-231-BR-HER2 models and Chapter 3 and 4 are limited to MDA-
MB-231-BR-HER2 only.  
The analysis of tumor permeability was qualitative in nature and was constrained to the 
extravasation of Gd-based contrast agent at endpoint (Chapter 2) or two time points post-
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radiotherapy (Chapter 3). DCE-MRI could be employed for a quantitative assessment of 
vascular permeability and tumor perfusion, which may be more sensitive to changes in 
tumor permeability than contrast-enhanced T1-weighted images alone [4]. Gd was 
selected as a contrast agent for these studies because it allowed for investigation of BBB 
integrity in vivo. The use of additional contrast agents, with different sizes and 
compositions, may more fully characterize the extent of BBB disruption [5]. Moreover, 
imaging at additional time points, though expensive, may provide insight into the 
dynamic nature of BBB permeability during metastatic tumor growth.  
MRI cell tracking of cancer cells with iron oxide nanoparticles is limited by its inability 
to discern cell viability, potential for bystander labeling, and challenges regarding cell 
quantification. It is impossible to know with certainty that the signal voids observed in 
Chapter 4 represent live dormant cancer cells. Validation of imaging data is relatively 
straightforward with PPB staining or fluorescence microscopy at early time points when 
there are many iron-labeled cells; however, it is extremely challenging at late time points 
when dormant cells are a rare cell population. We believe at least some of the signal 
voids discussed in Chapter 4 are live dormant cancer cells based on previous work by 
Heyn and colleagues who also described a subpopulation of iron-labeled non-
proliferative cancer cells in the brain, as well as results presented by Magnitsky and 
colleagues who found iron-labeled cancer cells alongside some bystander labeled 
macrophages in vivo [6, 7]. In addition, our lab recently demonstrated the ability to 
recover cells that are both iron-positive GFP-positive - indicating iron-labeled cancer 
cells - from the mouse brain, as characterized by flow cytometry (in press, Hamilton et 
al. Tomography). Moreover, in our experience, dead cells and iron-labeled immune cells 
tend to move within an organ and clear over time. Future work aimed at recovering 
dormant cancer cells would be valuable. Complimentary strategies to determine viability 
would also be useful and are further discussed in “Future Work.” Finally, accounting for 
cell and tumor burden is challenging using cellular MRI because cell quantification 
within a signal void is not possible and micro-metastatic burden is not detected in bSSFP 
images at 100x100x200 µm resolution. In this thesis, the number of signal voids was 
manually quantified as a surrogate measure for solitary cancer cells and micro-metastases 
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were evaluated in histology. A semi-automated approach for void quantification, such as 
percent black pixels or signal void volume, would be more efficient and is in 
development. Fluorine-19 is an alternative imaging agent for quantitative cell tracking 
that may be more accurate than iron-labeled techniques; however it does not have 
sufficient sensitivity for single cell detection [8]. Higher resolution bSSFP imaging would 
visualize smaller tumors, but is not desirable for our purposes due to the increased scan 
time and cost.  
5.3 Future Work 
Future work will translate the bSSFP tumor imaging technique used in our preclinical 
experiments from mouse to human brain imaging in the clinic. In addition, future 
research that expands on tracking and characterizing non-proliferative cancer cells after 
treatment would provide invaluable insight into cancer dormancy. 
5.3.1 Clinical Translation of bSSFP for Tumor Detection 
The preclinical results described in Chapters 2 and 3 demonstrate that contrast-enhanced 
MRI underestimates brain metastatic burden in mice due to heterogeneity in BBB 
integrity associated with tumors. This finding, along with previous research by Percy et 
al. suggests bSSFP MRI is advantageous for detecting small, Gd-impermeable tumors; 
moreover, this method can often detect tumors before they become visible in contrast-
enhanced MRI [9]. Importantly, it has not yet been studied if this result is consistent in 
humans and further investigation of this imaging technique in patients is warranted. Our 
group recently translated the preclinical bSSFP imaging technique to a small clinical 
study to evaluate the utility of bSSFP imaging for visualizing additional Gd-impermeable 
tumors in brain metastatic breast cancer patients.  Future work could explore the 
relationship between tumor contrast in bSSFP images and cancer subtype or 
histopathological features. Radiomic analysis may also be useful to quantify brain 
metastasis features in bSSFP and other clinically relevant sequences (T1 pre- and post-
Gd, T2), which could be used to predict patient outcomes and treatment response.  
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5.3.2 Bioluminescence Imaging 
Bioluminescence imaging (BLI) may be useful as a complementary imaging technique to 
provide information about cell viability in future experiments, since cellular MRI is 
unable to differentiate between live and dead iron-labeled cells. This imaging modality 
detects visible light that is emitted during luciferase-mediated oxidation of a luciferin 
substrate and requires ATP as a co-factor; therefore, it can be inferred that all detected 
light must have been produced from live cells [10]. Engineering the MDA-MB-231-BR-
HER2 cell line with a BLI reporter, such as firefly luciferase, would allow for 
quantitative BLI imaging of viable cancer cell burden in parallel with MRI-based cell 
tracking and concurrent tumor imaging. Characterization of the new luc+ cell line would 
be required to confirm that its proliferation, metastatic efficiency, and non-proliferative 
cell population is not significantly different from the luc- cell line studied in this thesis. 
Experiments should be performed to develop an optimal BLI protocol for brain 
metastasis imaging and confirm that labeling cells with iron oxide nanoparticles will not 
affect detection or quantification of brain tumor burden using BLI. It would also be 
interesting to explore the detection threshold for disseminated luc+ iron-labeled cells in 
the mouse brain with the ultimate goal of discerning whether residual voids observed in 
the brain after early radiotherapy are alive or not.  
5.3.3 Ex Vivo Brain Metastasis Assay 
Discerning if non-proliferative cancer cells are clonogenic is important to understand the 
potential for future tumor recurrence. The cellular MRI results presented in Chapter 4 
suggest non-proliferative cancer cells persist for extended periods of time; however, the 
metastatic nature of the MDA-MB-231-BR-HER2 model hinders investigation of 
clonogenicity in the long-term because development of extra-cranial disease ultimately 
limits the duration of study in this model. Naumov and colleagues previously recovered 
dormant cancer cells from the mouse liver and found that they were proliferative in vitro 
[11]. This strategy has been unsuccessful thus far in the brain metastatic model because 
there are few dormant cancer cells to recover and rare cell populations are challenging to 
isolate and expand in vitro. An ex vivo brain metastasis assay would be useful to extend 
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observation of non-proliferative cells and could provide a mechanism for interventions 
that may prompt dormant cells to re-awaken. Mendoza and colleagues created such a 
model, the pulmonary metastasis assay (PuMA), for studying metastasis formation and 
treatment in the lung; it may be possible that this strategy could be adapted for brain [12]. 
Preliminary studies would require optimizing perfusion and culture media for brain tissue 
survival, in order to preserve the brain architecture in vitro for 3-4 weeks or more. 
Following this, pilot studies using mouse brain with seeded cancer cells would be 
required to confirm the brain slices can host metastatic growth in vitro. Depending on the 
cell engineering, this growth could be quantified by histopathology, fluorescence 
microscopy, or BLI. Ultimately, this ex vivo assay could be initiated to extend 
observation in any brain metastasis model when extracranial disease requires 
euthanization of the animal. In particular, excising the brain at necropsy and maintaining 
it in culture using this assay would facilitate prolonged observation of non-proliferative 
cancer cells in the early radiotherapy model (Ch. 4). The increased study time may 
provide an opportunity for the non-proliferative cells to ‘re-awaken’ naturally or with 
growth supplements in order to determine their clonogenic potential.  
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